Partially crimped stent

Information

  • Patent Grant
  • 11839562
  • Patent Number
    11,839,562
  • Date Filed
    Monday, April 5, 2021
    3 years ago
  • Date Issued
    Tuesday, December 12, 2023
    a year ago
Abstract
A crimping method that crimps a stent over multiple catheters. The method includes differentially crimping a stent on certain portions of a balloon catheter so that a second catheter can be threaded through the uncrimped portion of the stent and exit through the links of a conventional stent design or through a specific hole in the stent designed for a branched vessel.
Description
BACKGROUND OF THE INVENTION

The present invention relates to the field of medical stents and, more particularly, for the treatment of lesions and other problems in or near a vessel bifurcation. A stent is an endoprosthesis scaffold or other device that typically is intraluminally placed or implanted within a vein, artery, or other tubular body organ for treating an occlusion, stenosis, aneurysm, collapse, dissection, or weakened, diseased, or abnormally dilated vessel or vessel wall, by expanding the vessel or by reinforcing the vessel wall. In particular, stents are quite commonly implanted into the coronary, cardiac, pulmonary, neurovascular, peripheral vascular, renal, gastrointestinal and reproductive systems, and have been successfully implanted in the urinary tract, the bile duct, the esophagus, the trachea-bronchial tree and the brain, to reinforce these body organs. Two important current widespread applications for stents are for improving angioplasty results by preventing elastic recoil and remodeling of the vessel wall and for treating dissections in blood vessel walls caused by balloon angioplasty of coronary arteries, as well as peripheral arteries, by pressing together the intimal flaps in the lumen at the site of the dissection. Conventional stents have been used for treating more complex vascular problems, such as lesions at or near bifurcation points in the vascular system, where a secondary artery branches out of a typically larger, main artery, with limited success rates.


Conventional stent technology is relatively well developed. Conventional stent designs typically feature a straight tubular, single type cellular structure, configuration, or pattern that is repetitive through translation along the longitudinal axis. In many stent designs, the repeating structure, configuration, or pattern has strut and connecting balloon catheter portions that impede blood flow at bifurcations.


Furthermore, the configuration of struts and connecting balloon catheter portions may obstruct the use of post-operative devices to treat a daughter vessel in the region of a vessel bifurcation. For example, deployment of a first stent in the mother lumen may prevent a physician from inserting a daughter stent through the ostium of a daughter vessel of a vessel bifurcation in cases where treatment of the mother vessel is suboptimal because of displaced diseased tissue (for example, due to plaque shifting or “snow plowing”), occlusion, vessel spasm, dissection with or without intimal flaps, thrombosis, embolism, and/or other vascular diseases.


A regular stent is designed in view of conflicting considerations of coverage versus access. For example, to promote coverage, the cell structure size of the stent may be minimized for optimally supporting a vessel wall, thereby preventing or reducing tissue prolapse. To promote access, the cell size may be maximized for providing accessibility of blood flow and of a potentially future implanted daughter stent to daughter vessels, thereby preventing “stent jailing,” and minimizing the amount of implanted material. Regular stent design has typically compromised one consideration for the other in an attempt to address both. Problems the present inventors observed involving daughter jailing, fear of plaque shifting, total occlusion, and difficulty of the procedure are continuing to drive the present inventors' into the development of novel, delivery systems, which are easier, safer, and more reliable to use for treating the above-indicated variety of vascular disorders.


Although conventional stents are routinely used in clinical procedures, clinical data shows that these stents are not capable of completely preventing in-stent restenosis (SR) or restenosis caused by intimal hyperplasia. In-stent restenosis is the reoccurrence of the narrowing or blockage of an artery in the area covered by the stent following stent implantation. Patients treated with coronary stents can suffer from in-stent restenosis.


Many pharmacological attempts have been made to reduce the amount of restenosis caused by intimal hyperplasia. Many of these attempts have dealt with the systemic delivery of drugs via oral or intravascular introduction. However, success with the systemic approach has been limited.


Systemic delivery of drugs is inherently limited since it is difficult to achieve constant drug delivery to the afflicted region and since systemically administered drugs often cycle through concentration peaks and valleys, resulting in time periods of toxicity and ineffectiveness. Therefore, to be effective, anti-restenosis drugs should be delivered in a localized manner.


One approach for localized drug delivery utilizes stents as delivery vehicles. For example, stents seeded with transfected endothelial cells expressing bacterial beta-galactosidase or human tissue-type plasminogen activator were utilized as therapeutic protein delivery vehicles. See, e.g., Dichek, D. A. et al., “Seeding of Intravascular Stents With Genetically Engineered Endothelial Cells,” Circulation, 80:1347-1353 (1989).


U.S. Pat. No. 5,679,400, International Patent Application WO 91/12779, entitled “intraluminal Drug Eluting Prosthesis,” and International Patent Application WO 90/13332, entitled “Stent With Sustained Drug Delivery” disclose stent devices capable of delivering antiplatelet agents, anticoagulant agents, antimigratory agents, antimetabolic agents, and other anti-restenosis drugs.


U.S. Pat. Nos. 6,273,913, 6,383,215, 6,258,121, 6,231,600, 5,837,008, 5,824,048, 5,679,400 and 5,609,629 teach stents coated with various pharmaceutical agents such as Rapamycin, 17-beta-estradiol, Taxol and Dexamethasone. This and all other referenced patents are incorporated herein by reference in their entirety. Furthermore, where a definition or use of a term in a reference, which is incorporated by reference herein is inconsistent or contrary- to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.


BRIEF SUMMARY OF THE INVENTION

The present invention relates to delivery catheters for delivery of stents for placement at vessel bifurcations and is generally configured to at least partially cover a portion of a daughter vessel as well as a mother vessel. The invention comprises stent crimping methods to differentially crimp a stent to account for stent design elements such as a tapered stent that does not have uniform walls. Additionally, differential crimping can be applied to stents that are mounted on two catheters.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented to provide what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the invention may be embodied in practice. In the drawings:



FIG. 1 is a cross sectional view of one embodiment with the mother catheter an over the wire design and the daughter catheter with a rapid exchange.



FIG. 2 is a cross sectional view of one embodiment with the daughter catheter an over the wire design and the mother catheter with a rapid exchange.



FIG. 3 is a cross sectional view of one embodiment with both mother and daughter catheters with rapid exchange design.



FIG. 4 is a cross sectional view of one embodiment with both mother and daughter catheters with an over the wire design.



FIG. 5 is a cross sectional view of one embodiment with the mother catheter an over the wire design, the daughter catheter with a rapid exchange, and a capture tube.



FIG. 6 is a cross sectional view of one embodiment with the daughter catheter an over the wire design, the mother catheter with a rapid exchange, and a capture tube.



FIG. 7 is a cross sectional view of one embodiment with both mother and daughter catheters with rapid exchange design, and a capture tube.



FIG. 8 is a cross sectional view of one embodiment both mother and daughter catheters with an over the wire design, and a capture tube.



FIG. 9 is a cross sectional view of one embodiment with the mother catheter an over the wire design, the daughter catheter with a rapid exchange, and a removable capture tube.



FIG. 10 is a cross sectional view of one embodiment with the daughter catheter an over the wire design, the mother catheter with a rapid exchange, and a removable capture tube.



FIG. 11 is a cross sectional view of one embodiment with both mother and daughter catheters with rapid exchange design, and a capture tube.



FIG. 12 is a cross sectional view of one embodiment with both mother and daughter catheters with an over the wire design, and a capture tube.



FIG. 13 is a cross sectional view of one embodiment with the mother catheter an over the wire design, the daughter catheter with a rapid exchange, and a short zipper.



FIG. 14 is a cross sectional view of one embodiment with the daughter catheter an over the wire design, the mother catheter with a rapid exchange, and a short zipper.



FIG. 15 is a cross sectional view of one embodiment with both mother and daughter catheters with rapid exchange design, and a short zipper.



FIG. 16 is a cross sectional view of one embodiment with both mother and daughter catheters with an over the wire design, and a short zipper.



FIG. 17 is a cross sectional view of one embodiment with the mother catheter an over the wire design and the daughter catheter with a rapid exchange, and an end to end zipper.



FIG. 18 is a cross sectional view of one embodiment with the daughter catheter an over the wire design, the mother catheter with a rapid exchange, and an end to end zipper.



FIG. 19 is a cross sectional view of one embodiment with both mother and daughter catheters with rapid exchange design, and an end to end zipper.



FIG. 20 is a cross sectional view of one embodiment with both mother and daughter catheters with an over the wire design, and an end to end zipper.



FIG. 21 is a cross sectional view of one embodiment with the mother catheter an over the wire design and the daughter catheter with a rapid exchange with a commercially available catheter.



FIG. 22 is a cross sectional view of one embodiment with the daughter catheter an over the wire design and the mother catheter with a rapid exchange with a commercially available catheter.



FIG. 23 is a cross sectional view of one embodiment with both mother and daughter catheters with rapid exchange design with a commercially available catheter.



FIG. 24 is a cross sectional view of one embodiment with both mother and daughter catheters with an over the wire design with a commercially available catheter.



FIGS. 25-30 illustrate the delivery sequence of a preferred embodiment in eight steps.



FIG. 31 is a photograph of a preferred embodiment with a bifurcation stent partially crimped.



FIG. 32 is a photograph of a preferred embodiment with a bifurcation stent partially crimped with a second catheter threaded through the bifurcation stent hole.



FIG. 33 is a photograph of a preferred embodiment with a bifurcation stent partially crimped with a second catheter threaded through the bifurcation stent hole.



FIG. 34 is a photograph of a preferred embodiment with the system fully aligned and fully crimped.



FIG. 35 is a cross sectional view of a differentially crimped stent on two catheters.



FIG. 36 is a profile view of a stent mounted on two balloon catheters.



FIG. 37 is a profile view of a stent mounted on two balloon catheters.





DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to delivery catheters for delivery of stents for placement at vessel bifurcations and is generally configured to at least partially cover a portion of a daughter vessel as well as a mother vessel. In particular, the present invention relates to novel methods of crimping stents to delivery catheters.


A variety of catheter designs may be employed to deploy and position the mother and daughter stents. Such catheters may be used in connection with multiple guidewires that terminate in the mother and daughter vessels. These guidewires may be used to facilitate introduction of the catheter, any angioplasty balloons, any stents, and/or to properly orient the stent or balloon within the vessel.


In general, the methods of the invention may utilize a catheter system comprising a catheter body having a mother vessel guidewire lumen and a daughter vessel balloon that is independently operable and coupled to the catheter body. The daughter balloon catheter portion has a daughter vessel guidewire lumen. The catheter system further includes mother catheter balloon, and a stent is disposed over the balloon. The daughter catheter portion extends into the proximal opening of the mother stent and exits the mother stent through a side passage of the mother stent.


According to one method, a mother vessel guidewire is inserted into the mother vessel until a distal end of the mother vessel guidewire passes beyond the ostium of the daughter vessel, and a daughter vessel guidewire is inserted into the mother vessel until a distal end of the daughter vessel guidewire passes into the daughter vessel. To prevent the crossing of guidewires, the two vessels are wired through a guidewire catheter with two lumens to keep the guidewires separate and untangled. This guidewire catheter is then removed and a wire separator is placed on the wires to keep the guidewires unwrapped. The catheter system is then advanced over the mother and daughter vessel guidewires, with the mother and daughter vessel catheters passing over the mother vessel guidewire and the daughter vessel guidewire. The catheter system is advanced on both wires with the daughter vessel balloon catheter portion distal to the mother balloon catheter portion. As the catheter system advances over the wires, the daughter vessel balloon will enter the daughter vessel and may be deployed immediately or simultaneously with the mother vessel balloon after placement of the mother vessel balloon. The mother balloon catheter portion of the catheter system is then advanced distally as far as it can be advanced to the bifurcation site because the tension of the daughter catheter on the mother stent will prevent the mother catheter from moving distally. This method facilitates advancement of the catheter system to the bifurcation, which may be necessary for tortuous or calcified coronaries. Once the catheter system is in place the daughter vessel balloon catheter portion is then pulled back relative to the mother catheter so that it is partially within the mother stent, alignment can be performed with radiopaque markers. The operator can then gently push the catheter system distal to maximize apposition to the carina. The daughter balloon is then inflated to ensure proper alignment of the mother stent. The daughter balloon may also have a stent on its distal portion, which would result in the proximal portion of the mother stent and the daughter stent to expand simultaneously. The daughter balloon is then deflated. The mother balloon is then inflated which deploys the mother stent. Kissing, reinflation, of the two balloons is done if necessary or for shifting plaque. The catheter system may be removed while the wires remain in place. The daughter vessel can be stented if necessary with any commercially available stent for example a short stent that would not cover the entire daughter balloon. The two vessels may be angioplastied separately as necessary predilatation is indicated on occasion.


In an alternative method, the mother catheter can be mounted on the daughter vessel guidewire and the daughter catheter can be mounted on the mother vessel guidewire. In daughter vessels with a high degree of angularity, over 60-70%, the friction is lower when the operator needs to draw the daughter stent proximal and into the mother stent in this configuration. The catheter system is advanced so the daughter balloon catheter can pass the ostium of the daughter vessel and remain in the mother vessel. As the catheter system is advanced further, the mother balloon catheter will enter the daughter vessel. The catheter system can only be advanced to the bifurcation because there is tension between the daughter catheter in the mother vessel and mother stent on the mother catheter that prevents further advancement. While the mother catheter is held in place, the daughter catheter is drawn back such that the proximal portion of the daughter balloon is in the mother stent. Alignment is performed with radiopaque markers. The operator can then gently push the catheter system distal to maximize apposition to the carina. A stent on the daughter balloon is aligned so that when the daughter balloon is inflated the daughter stent and the proximal portion of the mother stent expand simultaneously and give complete coverage of the mother vessel. The daughter vessel balloon is then deflated. The mother vessel balloon is then inflated and the distal portion of the mother stent is expanded. A kissing procedure can also be performed if required.


In an alternative embodiment, the system can be used for provisional stenting of the daughter vessel. The catheter system comprising mother catheter comprising a mother balloon and mother stent, and a daughter catheter comprising a daughter balloon wherein the mother catheter is loaded onto a daughter vessel guidewire and the daughter catheter is loaded onto the mother vessel guidewire. The catheter system is advanced so the daughter balloon catheter can pass the ostium of the daughter vessel and remain in the mother vessel. As the catheter system is advanced further, the mother catheter and mother stent will enter the daughter vessel. The catheter system can only be advanced to the bifurcation because there is tension between the daughter catheter in the mother vessel and mother stent on the mother catheter that prevents further advancement. While the mother catheter is held in place, the daughter catheter is drawn back such that the proximal portion of the daughter balloon is in the mother stent. Alignment is performed with radiopaque markers. The operator can then gently push the catheter system distal to maximize apposition to the carina. A balloon on a wire could be used as an alternative to the daughter catheter.


In an alternative embodiment, the system can be used for provisional stenting of the daughter vessel. The catheter system comprising; a mother catheter comprising a mother balloon and, a daughter catheter comprising a daughter balloon and a daughter stent on the distal portion of the daughter balloon wherein the mother catheter is loaded onto a mother vessel guidewire and the daughter catheter is loaded onto the daughter vessel guidewire. The catheter system is advanced on both wires with the daughter balloon catheter portion distal to the mother balloon catheter portion. As the catheter system advances over the wires, the daughter balloon will enter the daughter vessel. The mother balloon catheter portion of the catheter system is then advanced distally as far as it can be advanced to the bifurcation. Once the catheter system is in place the daughter vessel balloon catheter portion is then pulled back relative to the mother catheter so that it is partially within the mother vessel, alignment can be performed with radiopaque markers. The operator can then gently push the catheter system distal to maximize apposition to the carina. The daughter balloon and mother balloon are simultaneously inflated. The mother vessel can be stented if necessary with any commercially available stent. A balloon on a wire could be used as an alternative to the daughter catheter.


In an alternative embodiment, the catheter system can be arranged with the daughter balloon portion proximal to the mother balloon portion forward over the guidewires to the bifurcation. In the case of the mother catheter on the mother guidewire, the alignment of the mother stent with the ostium of the daughter vessel occurs because tension between the daughter guidewire and mother stent on the mother catheter that prevents further advancement of the mother catheter. In the alternative case of the mother catheter on the daughter guidewire, the alignment of the mother stent with the ostium of the mother vessel occurs because tension between the mother guidewire and mother stent on the mother catheter that prevents further advancement of the mother catheter. In both cases the daughter stent is advanced distally into alignment with the mother stent and expanded.


In preferred embodiments, FIGS. 1 and 4 show the mother catheter is an Over-the-Wire (OTW) design and the daughter catheter is a Rapid-Exchange (RX) design with daughter catheter portion about 3 centimeters distal the mother catheter portion. The daughter balloon is placed just distal to the tip of the mother catheter, this arrangement minimizes the overall profile of the catheter system and allows maximal tracking of the arteries. The system may additionally have stents crimped over the balloons. The daughter stent may be approximately half the length of the daughter balloon or mother stent. The proximal end of the mother stent may be crimped only slightly to allow the daughter catheter balloon portion to operate independently, i.e. may be pushed or pulled without dislodging the mother stent. The method comprising the following steps:

    • 1. Advance the catheter system to bifurcation, daughter balloon catheter portion and mother balloon catheter portion in their respective vessels. The mother catheter is no longer able to advance because of the tension between the mother stent and daughter catheter.
    • 2. The daughter balloon proximal portion is drawn back into the mother stent and aligned with radiopaque markers.
    • 3. While holding both the mother and daughter catheters tightly, the operator pushes forward lightly.
    • 4. Inflate the daughter balloon and expand the daughter stent, approximately half of the daughter balloon distal portion will expand the “half-stent,” and half of the daughter balloon proximal portion will expand inside the mother vessel and partially expand the proximal portion of the mother stent.
    • 5. Once the daughter stent is fully deployed, then the mother balloon can be fully expanded to deploy the distal portion of the mother stent.
    • 6. A conventional Kissing procedure may be utilized to ensure full apposition.


In one particular aspect, the daughter balloon catheter portion may be used without a stem. This would allow perfect alignment of mother stent around the ostium of the daughter vessel. The daughter balloon would be used for the alignment as outlined in step three above, and expand the proximal portion of the mother stent.


In an alternative embodiment, FIG. 5 shows the mother catheter is an Over-the-Wire (OTW) design and the daughter catheter is a Rapid-Exchange (RX) design with daughter catheter balloon portion about 3 centimeters distal the mother catheter balloon portion. The system may additionally have stents crimped over the balloons. The daughter stent may be approximately half the length of the mother balloon or stmt. The proximal end of the mother stent may be crimped only slightly to allow the daughter catheter balloon portion to operate independently, so that it may be pushed or pulled without dislodging the mother stent. The method comprising the following steps:

    • 1. Looping the OTW so that one operator can hold both guide wires with one hand and then push both catheters with the other.
    • 2. Advance the catheter system to bifurcation, daughter balloon catheter portion and mother balloon catheter portion aligned in their respective vessels, as disclosed in steps two through three in the above embodiment.
    • 3. While holding both the mother and daughter catheters tightly, push the catheter system forward until the mother balloon catheter portion is stopped at the carina.
    • 4. Inflate the daughter balloon and expand the daughter stent, approximately half of the daughter balloon distal portion will expand the “half-stent,” and half of the daughter balloon proximal portion will expand inside the mother vessel and partially expand the proximal portion of the mother stem.
    • 5. Once the daughter stent is fully deployed, then the mother balloon can be fully expanded to deploy the distal portion of the mother stent.
    • 6. A conventional Kissing procedure may be utilized to ensure full apposition.


In one particular aspect, the daughter balloon catheter portion may be used without a stent. This would allow perfect alignment of mother stent around the ostium of the daughter vessel. The daughter balloon would be used for the alignment as outlined in step three above, and expand the proximal portion of the mother stent.


In an alternative embodiment, the mother catheter is an Over-the-Wire design and the daughter catheter is a Rapid-Exchange design with daughter catheter portion about 3 centimeters distal. The system may additionally have stents crimped over the balloons. The daughter stent may be approximately half the length of the mother balloon or stent. The proximal end of the mother stent may be crimped only slightly to allow the daughter catheter balloon portion to operate independently, i.e. may be pushed or pulled without dislodging the mother stent. The method comprising the following steps:

    • 1. Place the daughter guidewire only and then slide the system into the guide catheter. Just before exiting the guide catheter, insert the mother guide wire through the catheter and into the mother vessel, then push the system out of the guide catheter. To reduce wire wrap.
    • 2. Advance the catheter system to the bifurcation, daughter balloon catheter portion and mother balloon catheter portion aligned in their respective vessels.
    • 3. Advance the catheter system to bifurcation, daughter balloon catheter portion and mother balloon catheter portion aligned in their respective vessels, as disclosed in step two in the above embodiment.
    • 4. Inflate the daughter balloon and expand the daughter stent, approximately half of the daughter balloon distal portion will expand the “half-stent,” and half of the daughter balloon proximal portion will expand inside the mother vessel and partially expand the proximal portion of the mother stent.
    • 5. Once the daughter stent is fully deployed, then the mother balloon can be fully expanded to deploy the distal portion of the mother stent.
    • 6. A conventional Kissing procedure may be utilized to ensure full apposition.


In one particular aspect, the daughter balloon catheter portion may be used without a stent. This would allow perfect alignment of mother stent around the ostium of the daughter vessel. The daughter balloon would be used for the alignment as outlined in step three above, and expand the proximal portion of the mother stent.


In an alternative embodiment the mother and daughter systems balloons are aligned. This embodiment could include the mother stent and daughter stent or either stent. When there is both a mother stent and a daughter stent, the daughter stent would be approximately half the length of the mother stent so that the daughter stent could be mounted on the distal half of the daughter balloon. Further the proximal portion of the daughter catheter would be crimped under the mother stent. The dual stent arrangement would reduce the profile compared to a full length stent that covered the entire length of the daughter balloon.


The methods described herein could alternatively include the step of flushing the catheters and the guidewire port to assist with maneuverability. The methods described herein could alternatively include the step of a couple of snap-on couplers the catheters are locked together.


In another particular aspect, each balloon catheter portion may include at least one radiopaque marker. With such a configuration, separation of the markers may be conveniently observed using fluoroscopy to indicate that the balloon catheter portions have passed beyond the ostium and the daughter balloon catheter portion has passed into the daughter vessel, thus aligning the passage of the stent with the ostium of the daughter vessel.


In another particular aspect, the catheter systems design is contemplated to cover combinations of rapid exchange and over the wire; for visualization purposes the hybrid versions are preferred because they are easier to distinguish while using fluoroscopy.


In another particular aspect, the proximal balloon may be differentially expandable, such that one end of the balloon may expand prior to the other end. In another particular aspect, the proximal balloon catheter portion may receive a stent that can be crimped under variable pressure to allow the distal balloon catheter portion freedom of movement.


In another particular aspect, a stent may be crimped over the proximal balloon catheter portion and the stent may be designed to deploy with variable profile to better oppose the patient anatomy.


In another particular aspect, the distal balloon catheter portion may be delivered via a pull away.


All of the above embodiments may utilize mother vessel stents ranging from 2.5 to 5.0 millimeter in diameter and daughter vessel stent ranging from 2.0 to 5.0 millimeter in diameter. The length of the stents could be in the range of 4 to 40 millimeter. The position of a stent on a catheter is not fixed and can be positioned on either or both catheters.



FIG. 1 illustrates the catheter system 10 with a distal daughter balloon catheter portion 30 comprising a balloon 32 with a daughter stem 33 crimped (not shown). The daughter stent 33 may be shorter than the mother stent 23. In a particular embodiment the daughter stent 33 is half the length of the mother stent 23 (not shown). The distal daughter stent 33 is crimped under standard conditions known in the art. The proximal mother balloon catheter portion 20 comprises a mother balloon 22 and a mother stent 23. The mother stent 23 is crimped differentially along the longitudinal direction and circumferentially, FIGS. 36-37. In the particular embodiment, the distal half 23a of the mother stent 23 is crimped under typical conditions to ensure that the mother stent 23 is not dislodged during the alignment with the distal daughter balloon 32. Further, the proximal portion 23b of the mother stent 23 is crimped under non-standard, relatively loose, conditions to allow the distal daughter balloon catheter portion 30 freedom of movement even though a portion of the daughter balloon catheter portion 30 is circumferentially enclosed. The mother catheter 21 and daughter catheter 31 are slidably attached to each other via a hollow exchange port 40, The exchange port 40 is embedded in the side of the mother over the wire catheter. The exchange port 40 is 10 centimeters long with a diameter just large enough to allow the insertion of the rapid exchange daughter catheter and daughter 31 balloon 32. The exchange port 40 can vary in length from 1 centimeter to 30 centimeters. The entry for the daughter catheter 32 on the exchange port 40 is proximal and the exit for the daughter catheter 32 is on the distal end of the exchange port 40. The daughter catheter 32 is loaded through the exchange port 40 and the daughter balloon 32 extends distally 5 centimeters from the exit of the exchange port 40 5 centimeters. However, it is possible to have the exchange port 40 1 to 30 centimeters proximal to the mother balloon 22. The mother stent 23 can be crimped on to the balloon after it has been loaded through the exchange port 40. The exchange port 40 must have a tight fit to reduce catheter profile and have low friction to allow the operator to easily slide the catheters relative to each other.



FIG. 2 illustrates a cross sectional view of one embodiment with the mother catheter balloon portion 20 proximal to the daughter catheter balloon portion 30 utilizing the same exchange port 40 as described in FIG. 1. The daughter balloon 32 is 5 centimeters distal from the exit of the exchange port 40. As disclosed above, the daughter balloon 32 could be distal from the exchange 40 port 1 to 30 centimeters.



FIG. 3 illustrates a cross sectional view of one embodiment with the mother and daughter catheters both having a rapid exchange design. In this particular embodiment one of the catheters has an exchange port 40 embedded in its side and the other catheter is loaded through the exchange port 40. Typically, the catheter would have to be loaded prior to having a stent crimped over the balloon portion.



FIG. 4 illustrates a cross sectional view of one embodiment with the mother and daughter catheters both having an over the wire design. In this particular embodiment one of the catheters has an exchange port 40 embedded in its side and the other catheter does not have an exchange port. The catheter without the exchange port would be loaded onto the catheter with an exchange port 40. Typically, the catheter would have to be loaded prior to having a stent crimped over the balloon portion.



FIGS. 5-8 illustrate an end to end capture tube 41 that connects the catheters together. FIGS. 5-6 The capture tube 41 is a thin polymer hollow straw that covers the mother and daughter catheters from a point 10 centimeters distal the Indeflator® attachment 43 to a distal point that is 10 centimeters proximal from the rapid exchange catheter's proximal rapid exchange port 47. FIG. 7 discloses dual rapid exchange mother and daughter catheters so the end point of the capture tube 41 would be 10 centimeters proximal from the rapid exchange catheters' rapid exchange port 47 on the proximal catheter. FIG. 8 embodies a catheter system with dual over the wire designs, therefore the capture tube 41 ending point ends 30 centimeters proximal from the balloon portion of the most distal catheter. The capture tube 41 keeps the catheters from tangling. The capture tube 41 remains in place during the entire clinical procedure. FIG. 6 illustrates a distal daughter catheter 31 with an over the wire design and a proximal mother catheter 21 with a rapid exchange design. FIG. 5 illustrates a proximal mother catheter 21 with an over the wire design and a distal daughter catheter 31 with a rapid exchange design.



FIGS. 9-12 illustrate a removable capture tube 42 that is fitted over the dual catheters as described above but the capture tube 42 has a polymer appendage 44. Once the operator has the catheter system placed near the bifurcation the operator can grab hold of the polymer appendage 44 and pull the capture tube 42 off of the catheters. FIG. 10 illustrates a distal daughter catheter 31 with an over the wire design and a proximal mother catheter 21 with a rapid exchange design. FIG. 9 illustrates a proximal mother catheter 21 with an over the wire design and a distal daughter catheter 31 with a rapid exchange design. FIG. 11 illustrates a dual rapid exchange design with a removable capture tube 42. FIG. 12 illustrates a dual over the wire design with a removable capture tube 42.



FIGS. 13-16 illustrate a zipper 45 that allows one catheter to snap in to the other catheter. The zipper 45 is essentially a groove that forms a concave receiving cross section and is carved into a catheter's outer surface in a straight line. The groove can be a single groove over a certain portion of a catheter or it can run from end to end. Alternatively, the catheter can have a series of short grooves of 1 to 10 centimeters in length that run the length of the catheter or only a certain portion. Full length end to end zippers will have reduced profile and reduced friction with the vessel. The resulting groove can receive another catheter and prevent the catheters from dislodging while the operator is advancing the catheters to the bifurcation. Once at the site the operator can still slidably move the catheters forward and back relative to each other. Mother catheters that utilize the groove can have fully crimped stents as described in several of the embodiments above; however, it is possible to allow operators to choose any commercially available catheter with or without a stent and mount the commercially available catheter via the zipper 45. The mother catheters with an empty zipper 45 would have a mother stent 23 full crimped on the distal balloon portion 22a of the mother catheter 21. After loading the commercially available catheter the operator would have to crimp the proximal portion of the mother stent 23b in situ prior to beginning the clinical procedure. This option may be extremely valuable to operators who can reduce their total inventory of catheters but have more options for treating bifurcated lesions. FIG. 14 illustrates a distal daughter catheter 31 with an over the wire design and a proximal mother catheter 21 with a rapid exchange design and a short zipper 45. FIG. 13 illustrates a proximal mother catheter 21 with an over the wire design and a distal daughter catheter 31 with a short zipper 45. FIG. 15 illustrates a dual rapid exchange design with a short zipper 45. FIG. 16 illustrates a dual over the wire design with a short, zipper 45. FIG. 18 illustrates a distal daughter catheter 31 with an over the wire design and a proximal mother catheter 21 with a rapid exchange design and an end to end zipper 45, FIG. 17 illustrates a proximal mother catheter 21 with an over the wire design and a distal daughter catheter 31 with an end to end zipper 45. FIG. 19 illustrates a dual rapid exchange design with an end to end zipper 45. FIG. 20 illustrates a dual over the wire design with an end to end zipper 45.



FIGS. 21-24 illustrate commercially available catheters that can be used with an alternative embodiment where in the mother catheter 21 is provided to the operator with a mother stent 23 (not shown) that is crimped on the distal portion of the mother catheter balloon 22a. The proximal portion 23b of the mother stent 23 is uncrimped. The operator can mount any commercially available catheter or balloon on a wire through the end of the mother stent proximal portion 23b and exit out the side hole 25 of the mother stent 23. See FIG. 36, The operator can align the catheters to suit the patient's anatomy and crimp the proximal portion 23b of the mother stent 23. The operator can crimp the stent 23 tightly so that the catheters do not move relative to each other. It is possible for the operator to place the catheters at the bifurcation and if necessary pullback on the commercially available catheter to adjust the alignment if necessary. Then the operator can gently push the system distally to ensure complete apposition. FIG. 21 illustrates a distal daughter catheter 31 with a rapid exchange design and a proximal mother catheter 21 with an over the wire design. FIG. 22 illustrates a distal daughter catheter 31 with an over the wire design and a proximal mother catheter 21 with a rapid exchange design. FIG. 23 illustrates a dual rapid exchange design. FIG. 24 illustrates a dual over the wire design.


Alternative embodiments of commercially available catheters that are single use devices for treating a single vessel, but can be mated together in various combinations with a polymer sleeve. The operator chooses the two catheters for the patient's anatomy then slides a sized polymer sleeve over both catheters from the distal ends. Once the operator has the catheters aligned the polymer sleeve can be treated with a heat or light source to shrink and bond the two catheters together with friction. The polymer sleeve is made of typical polymers that can act as shrink wrap when treated with a heat or light source. The polymer of the polymer sleeve for example could be manufactured with polyolefin a chemical used in manufacturing shrink wrap. The polymer sleeve would not crosslink or covalently attach to the catheters, several types of polymers are commercially available and have the requisite properties, thin, strong, not adhesive, and reaction times to their source of ten minutes or less. The polymer sleeves are typically 15 centimeters in length and have various diameters to suit typical catheter diameters 4 French to 20 French. The operator can test that the bond is holding by applying slight pressure prior to the procedure. If the polymer sleeve does not hold tightly the operator may elect to use a smaller diameter polymer sleeve or use more than one polymer sleeve by placing the polymer sleeves adjacent to each other. Alternatively, several smaller sleeves from 1 to 10 centimeters in length could be placed over several different portions of the catheters.



FIGS. 25-30 illustrate the delivery sequence of a preferred embodiment in eight steps, Step 1 illustrates the introduction of a 0.035 inch guidewire 50 up to the bifurcation. Step 2 illustrates the tracking of a guide catheter 53 over the guidewire 50. Step 3 illustrates the removal of the guidewire 50 and placement position of the guide catheter 53. Step 4 illustrates the tracking and placement of a rapid exchange compatible wire 52 in the daughter vessel 2 and an over the wire compatible wire 51 in the mother vessel 1. Step 5A & 5B illustrate tracking of the catheter system 10 distally over both the guidewires. Step 6A illustrates the inflation of the daughter balloon 32 and placement of the daughter stent 33 and partial deployment of the mother stent 23. Step 6B illustrates the inflation of the mother balloon 22 to place the distal portion 23a of the mother stent 23 in the mother vessel 1. Step 7A illustrates the mother stent 23 in the main branch with side hole 25 facing the daughter vessel 2. Step 7B illustrates a bifurcated stent partially in the daughter vessel 2 and the mother vessel 1 where a side hole 25 of the mother stent 23 opens toward the main branch vessel 1.


In an alternative embodiment the delivery catheter mother balloons having tapered ends to accommodate balloons and stents with non-uniform profiles. For example, the proximal end of the daughter vessel stent may be designed to have a larger circumference than the distal end to compensate for the natural bifurcation anatomy. The daughter vessel balloon would like wise have a taper to properly expand the stent and ensure complete apposition. Additionally, it is possible to design the mother stent to expand differentially along its profile to compensate for a larger arterial diameter at the carina or ostium. In other words, the proximal and distal ends of the mother vessel balloon and mother vessel stent would be smaller in circumference while the center portion of the mother vessel stent would have a larger circumference.


In an alternative embodiment the mother vessel balloon having tapered ends to accommodate the distal balloon catheter portion and guidewire lumen. Further, the mother vessel balloon is designed for differential expansion to accommodate natural vessel anatomy.


In a preferred embodiment wherein the distal (daughter) balloon catheter portion is crimped with a half stent on a rapid exchange type design catheter. The daughter vessel stent is 4-20 millimeter and the daughter vessel balloon is approximately twice as long in length. The mother vessel stent 10-30 millimeter is differentially crimped to allow independent operation of the daughter balloon catheter portion. The distal portion of the mother vessel stent is crimped tightly enough to keep the entire stent from unintentionally dislodging during the procedure. The proximal portion of the mother vessel stent is crimped just tightly enough to reduce the crossing profile and allow the daughter balloon catheter portion to be moved distal or proximal relative to the mother balloon catheter portion. The proximal (mother) balloon catheter portion is an over the wire type design with the mother vessel balloon about 3 centimeters proximal to the daughter vessel balloon.


In an alternative embodiment a stent is designed to allow differential expansion of the middle portion of the stent relative to the proximal and distal ends. In particular, the design facilitates the placement of the stent across a bifurcation lesion in the mother vessel because it has a larger circumference in the middle portion relative to the ends than a stem with a constant profile. Further, the profile can be adjusted so that the largest circumference can be placed proximal or distal to the midpoint of the stent. In the particular embodiment the largest circumference is distal to the midpoint of the stent, but could be easily reversed for variable patient anatomy.


Partial crimping has the following key features that make it possible to maintain sufficient stent retention during delivery and placement and still allows the secondary system adjustability and deliverability. FIG. 31 is a partially crimped bifurcation stent prior to placement on any balloon catheter. FIGS. 32-34 illustrate an embodiment of the present invention in three steps. First, the bifurcation stent 23 is partially crimped over approximately one-third the distal portion 23a of the bifurcation stent on to the mother catheter 21 and the daughter catheter 31 is loaded through the mother catheter 21 and mother stent 23 where the daughter stent 33 can be crimped separately. Second, the daughter stent 33 is crimped and pulled back proximally to align the proximal end of the daughter stent 33 near the distal end of the mother stent 23. Third, the proximal portion of the mother stent 23b can be crimped to reduce the outer diameter, yet still allow independent movement of the two catheters relative to each other.



FIG. 35 illustrates a cross section of a daughter balloon catheter 31 without a daughter stent. The daughter catheter 31 is on top of the mother catheter 21, The mother stent 23 is differentially crimped around the mother catheter balloon 22 and daughter catheter 31 because the daughter catheter 31 profile is smaller than the mother catheter 21 profile. The differential crimping is non-uniform and can create various cross sectional shapes to accommodate different catheter designs, balloon designs, and stent designs. For example, pear shaped or a figure eight are possible configurations. The current embodiment is designed to reduce the profile as much as possible. In one preferred method of manufacturing, a protective sheet 46 is placed between the two catheters. The protective sheet 46 only needs to cover the portions that will come in contact during the crimping process, then the protective sheet 46 can be removed. FIG. 36 illustrates a side view of the mother stem 23 mounted on the mother catheter balloon 22 and the daughter catheter 31 mounted on the mother catheter 21 through the mother stent 22. The distal portion 23a of the mother stent 23 will be crimped under standard conditions to hold stent firmly to the mother balloon 22 and mother catheter 21, The proximal portion 23b of the mother stem 23 is partially crimped to reduce the profile, but still allows the daughter catheter 31 freedom to move proximal or distal relative to the mother catheter 21. This embodiment illustrates that the stent 23 is differentially crimped in both the circumferential and longitudinal direction. The amount of crimping will be determined by the stent design and size, catheter dimensions, and balloon dimensions; thus the crimping is differential along the longitudinal axis. FIG. 37 illustrates a side view of the mother stent 23 mounted on the mother catheter balloon 22 and the daughter catheter 31 mounted on the mother catheter 21 through the mother stent 23. The daughter catheter 31 also includes a stent 33 that can be crimped under standard conditions. The distal portion 23a of the mother stent 23 will be crimped under standard conditions to hold stent firmly to the mother balloon 22 and mother catheter 21. In one experiment, this arrangement was tested to determine the strength of the distal crimping of the mother stent 23 by pulling the daughter catheter 31 and daughter stent 33 proximally; the results were that the daughter catheter 31 successfully passed through the crimped mother stent 23 and still retained the daughter stent 33 as well.


Additional features may be utilized during the crimping process such as adding a slight positive internal pressure to the balloon so that the final balloon surface pillows about 0.002 inch beyond the outer diameter of the stent. This process can yield a design that protects the stent from engaging with the vessel thus reducing friction and improving stem retention at the same time. Further, this process improves safety and reduces trauma to the vessel.


While the above embodiment discloses a bifurcation stent that is crimped at or about its distal half; this is not a limitation. The stem could be differentially crimped along its axis depending upon stent design, for example; if a hole in the side of a stent was not centered along the axis. It may be preferential to have the distal crimped portion of the bifurcation stent extend just distal of the hole that the daughter catheter to pass through. Alternatively, the distal crimped portion could extend partially or entirely over the hole that the daughter catheter passes through.


While the invention has been described in conjunction with specific embodiments and examples thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art upon reading the present disclosure. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

Claims
  • 1. A method for treating a bifurcated vessel having a mother vessel and a daughter vessel, the method comprising: advancing a daughter catheter comprising a daughter expandable member through the mother vessel so that the daughter expandable member is advanced into the daughter vessel;advancing a mother catheter comprising a mother expandable member through the mother vessel so that a distal end of the mother expandable member advances distal to the daughter vessel;further advancing the mother catheter and daughter catheter into apposition with a carina of the bifurcation until a resulting tension between the mother and daughter catheters prevents further distal advancement of the mother catheter and the daughter catheter;retracting the daughter expandable member into a side hole of a mother stent crimped to the mother expandable member;expanding the daughter expandable member to expand a proximal portion of the mother stent into engagement with a portion of the mother vessel proximal to the daughter vessel and also to align the side hole with the daughter vessel; andexpanding the mother expandable member to expand a distal portion of the mother stent into engagement with a portion of the mother vessel distal to the daughter vessel.
  • 2. The method of claim 1, wherein the daughter catheter further comprises a daughter stent disposed over the daughter expandable member, and wherein expanding the daughter expandable member further comprises expanding the daughter stent into engagement with a portion of the daughter vessel.
  • 3. The method of claim 2, wherein the daughter stent expands simultaneously with the proximal portion of the mother stent.
  • 4. The method of claim 1, wherein retracting the daughter expandable member into the side hole further comprises retracing the daughter expandable member until a radiopaque marker on the daughter catheter is aligned with a radiopaque marker on the mother catheter.
  • 5. The method of claim 1, wherein expanding the daughter expandable member is independent of expanding the mother expandable member.
  • 6. The method of claim 1, further comprising delivering a therapeutic agent from the mother stent to the mother vessel or the daughter vessel.
  • 7. The method of claim 6, wherein the therapeutic agent is an anti-restenosis drug.
  • 8. The method of claim 1, further comprising kissing balloons by simultaneously inflating both the mother expandable member and the daughter expandable member to evenly expand the mother stent adjacent the bifurcation.
  • 9. The method of claim 1, wherein retracting the daughter catheter further comprises retracting the daughter catheter out of, and away from the proximal portion of the mother stent.
CROSS-REFERENCES TO RELATED APPLICATIONS

The present application is a Continuation of U.S. Ser. No. 15/661,975 filed Jul. 27, 2017 (Allowed) which is a Continuation of U.S. Ser. No. 14/317,387 filed Jun. 27, 2014, (now U.S. Pat. No. 9,737,424); which is a Divisional of U.S. Ser. No. 13/071,149 filed Mar. 24, 2011 (now U.S. Pat. No. 8,821,562); which is a Continuation of PCT Appln. No. PCT/US2009/058505 filed Sep. 25, 2009; which claims the benefit of U.S. Provisional Appln. No. 61/194,346 filed Sep. 25, 2008; the entire contents which are incorporated herein by reference in their entirety for all purposes. The present application is related to U.S. application Ser. No. 13/071,251 (now U.S. Pat. No. 8,979,917); Ser. No. 13/071,239 (now U.S. Pat. No. 8,769,796); Ser. No. 13/071,198 (now U.S. Pat. No. 8,795,347); Ser. No. 13/071,183 (now U.S. Pat. No. 8,808,347); and Ser. No. 13/071,162 (now U.S. Pat. No. 8,828,071), all of which were filed on Mar. 24, 2011 and are incorporated herein by reference in their entirety for all purposes. The present application is also related to U.S. Provisional Appln. Nos. 61/317,198; 61/317,114; 61/317,121; and 61/317,130; all of which were filed on Mar. 24, 2010, and are incorporated herein by reference in their entirety for all purposes.

US Referenced Citations (587)
Number Name Date Kind
4069825 Akiyama Jan 1978 A
4468224 Enzmann et al. Aug 1984 A
4512338 Balko et al. Apr 1985 A
4564014 Fogarty et al. Jan 1986 A
4580568 Gianturco Apr 1986 A
4681110 Wiktor Jul 1987 A
4690684 Mcgreevy et al. Sep 1987 A
4733665 Palmar Mar 1988 A
4739762 Palmaz Apr 1988 A
4762129 Bonzel Aug 1988 A
4770176 Mcgreevy et al. Sep 1988 A
4775337 Van Wagener et al. Oct 1988 A
4776337 Palmaz Oct 1988 A
4886062 Wiktor Dec 1989 A
4891225 Langer et al. Jan 1990 A
4988356 Crittenden et al. Jan 1991 A
4994066 Voss Feb 1991 A
4994069 Ritchart et al. Feb 1991 A
5013318 Spranza, III May 1991 A
5040548 Yock Aug 1991 A
5064435 Porter Nov 1991 A
5092877 Pinchuk Mar 1992 A
5102417 Palmaz Apr 1992 A
5104404 Wolff Apr 1992 A
5122154 Rhodes Jun 1992 A
5135535 Kramer Aug 1992 A
5171222 Euteneuer et al. Dec 1992 A
5195984 Schatz Mar 1993 A
5217495 Kaplan et al. Jun 1993 A
5219355 Parodi et al. Jun 1993 A
5226913 Pinchuk Jul 1993 A
5246421 Saab Sep 1993 A
5273536 Savas Dec 1993 A
5282824 Gianturco Feb 1994 A
5300085 Yock Apr 1994 A
5312415 Palermo May 1994 A
5334187 Fischell et al. Aug 1994 A
5403341 Solar Apr 1995 A
5421955 Lau et al. Jun 1995 A
5456694 Marin et al. Oct 1995 A
5456713 Chuter Oct 1995 A
5458615 Klemm et al. Oct 1995 A
5478349 Nicholas Dec 1995 A
5490837 Blaeser et al. Feb 1996 A
5496346 Horzewski et al. Mar 1996 A
5501227 Yock Mar 1996 A
5507768 Lau et al. Apr 1996 A
5507771 Gianturco Apr 1996 A
5514093 Ellis et al. May 1996 A
5514154 Lau et al. May 1996 A
5527354 Fontaine et al. Jun 1996 A
5549551 Peacock, III et al. Aug 1996 A
5549563 Kronner Aug 1996 A
5549635 Solar Aug 1996 A
5554181 Das Sep 1996 A
5562725 Schmitt et al. Oct 1996 A
5571086 Kaplan et al. Nov 1996 A
5591228 Edoga Jan 1997 A
5593412 Martinez et al. Jan 1997 A
5607444 Lam Mar 1997 A
5607463 Schwartz et al. Mar 1997 A
5609627 Goicoechea et al. Mar 1997 A
5609629 Fearnot et al. Mar 1997 A
5628775 Jackson et al. May 1997 A
5632763 Glastra May 1997 A
5632772 Alcime et al. May 1997 A
5634928 Fischell et al. Jun 1997 A
5639274 Fischell et al. Jun 1997 A
5662675 Polanskyj Stockert et al. Sep 1997 A
5669924 Shaknovich Sep 1997 A
5670161 Healy et al. Sep 1997 A
5676654 Ellis et al. Oct 1997 A
5679400 Tuch Oct 1997 A
5683451 Lenker et al. Nov 1997 A
5697948 Marin et al. Dec 1997 A
5697967 Dinh et al. Dec 1997 A
5702418 Ravenscroft Dec 1997 A
5709701 Parodi Jan 1998 A
5716393 Lindenberg et al. Feb 1998 A
5722669 Shimizu et al. Mar 1998 A
5723003 Winston et al. Mar 1998 A
5735869 Fernandez-Aceytuno Apr 1998 A
5741323 Pathak et al. Apr 1998 A
5749825 Fischell et al. May 1998 A
5749848 Jang et al. May 1998 A
5749921 Lenker et al. May 1998 A
5755734 Richter et al. May 1998 A
5755735 Richter et al. May 1998 A
5755771 Penn et al. May 1998 A
5755772 Evans et al. May 1998 A
5755776 Al-Saadon May 1998 A
5755781 Jayaraman May 1998 A
5769882 Fogarty et al. Jun 1998 A
5772669 Vrba Jun 1998 A
5776141 Klein et al. Jul 1998 A
5797951 Mueller Aug 1998 A
5800519 Sandock Sep 1998 A
5807398 Shaknovich Sep 1998 A
5824040 Cox et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824048 Tuch Oct 1998 A
5827320 Richter et al. Oct 1998 A
5833694 Poncet Nov 1998 A
5836964 Richter et al. Nov 1998 A
5837008 Berg et al. Nov 1998 A
5843092 Heller et al. Dec 1998 A
5855563 Kaplan et al. Jan 1999 A
5858556 Eckert et al. Jan 1999 A
5870381 Kawasaki et al. Feb 1999 A
5879370 Fischell et al. Mar 1999 A
5891190 Boneau Apr 1999 A
5893887 Jayaraman Apr 1999 A
5895398 Wensel et al. Apr 1999 A
5899935 Ding May 1999 A
5902332 Schatz May 1999 A
5911754 Kanesaka et al. Jun 1999 A
5919175 Sirhan Jul 1999 A
5922020 Klein et al. Jul 1999 A
5961536 Mickley et al. Oct 1999 A
5968069 Dusbabek et al. Oct 1999 A
5972017 Berg et al. Oct 1999 A
5972027 Johnson Oct 1999 A
5976107 Mertens et al. Nov 1999 A
5976155 Foreman et al. Nov 1999 A
5980484 Ressemann et al. Nov 1999 A
5980486 Enger Nov 1999 A
5980514 Kupiecki et al. Nov 1999 A
5980552 Pinchasik et al. Nov 1999 A
5984957 Lapewicz, Jr. et al. Nov 1999 A
5997563 Kretzers Dec 1999 A
6004328 Solar et al. Dec 1999 A
6007517 Anderson Dec 1999 A
6017363 Hojeibane Jan 2000 A
6022359 Frantzen Feb 2000 A
6022374 Imran Feb 2000 A
6033434 Borghi Mar 2000 A
6036725 Avellanet Mar 2000 A
6039721 Johnson et al. Mar 2000 A
6042589 Marianne Mar 2000 A
6048361 Von Oepen Apr 2000 A
6056722 Jayaraman May 2000 A
6056775 Borghi et al. May 2000 A
6059811 Pinchasik et al. May 2000 A
6059824 Taheri May 2000 A
6063092 Shin May 2000 A
6066155 Amann et al. May 2000 A
6068655 Seguin et al. May 2000 A
6070589 Keith et al. Jun 2000 A
6086604 Fischell et al. Jul 2000 A
6090063 Makower et al. Jul 2000 A
6090136 Mcdonald et al. Jul 2000 A
6096071 Yadav Aug 2000 A
6096073 Webster et al. Aug 2000 A
6099497 Adams et al. Aug 2000 A
6102942 Ahari Aug 2000 A
6106530 Harada Aug 2000 A
RE36857 Euteneuer et al. Sep 2000 E
6117117 Mauch Sep 2000 A
6120522 Vrba et al. Sep 2000 A
6123712 Di Caprio et al. Sep 2000 A
6123723 Konya Sep 2000 A
6126685 Lenker et al. Oct 2000 A
6129738 Lashinski et al. Oct 2000 A
6129756 Kugler et al. Oct 2000 A
6132460 Thompson Oct 2000 A
6136011 Stambaugh Oct 2000 A
6142973 Carleton et al. Nov 2000 A
6143016 Bleam et al. Nov 2000 A
6165167 Delaloye Dec 2000 A
6165210 Lau et al. Dec 2000 A
6179878 Duerig et al. Jan 2001 B1
6183509 Dibie Feb 2001 B1
6187034 Frantzen Feb 2001 B1
6190402 Horton et al. Feb 2001 B1
6196995 Fagan Mar 2001 B1
6200337 Moriuchi et al. Mar 2001 B1
6210429 Vardi et al. Apr 2001 B1
6221090 Wilson Apr 2001 B1
6231600 Zhong May 2001 B1
6238991 Suzuki May 2001 B1
6241691 Ferrera et al. Jun 2001 B1
6251132 Ravenscroft et al. Jun 2001 B1
6251134 Alt et al. Jun 2001 B1
6254612 Hieshima Jul 2001 B1
6254628 Wallace et al. Jul 2001 B1
6258117 Camrud et al. Jul 2001 B1
6258121 Yang et al. Jul 2001 B1
6264682 Wilson et al. Jul 2001 B1
6264688 Herklotz et al. Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6273895 Pinchuk et al. Aug 2001 B1
6273911 Cox et al. Aug 2001 B1
6273913 Wright et al. Aug 2001 B1
6312458 Golds Nov 2001 B1
6315794 Richter Nov 2001 B1
6319275 Lashinski et al. Nov 2001 B1
6319277 Rudnick et al. Nov 2001 B1
6322586 Monroe et al. Nov 2001 B1
6325823 Horzewski et al. Dec 2001 B1
6325826 Vardi et al. Dec 2001 B1
6326826 Lee et al. Dec 2001 B1
6334871 Dor et al. Jan 2002 B1
6344053 Boneau Feb 2002 B1
6344056 Dehdashtian Feb 2002 B1
6344272 Oldenburg et al. Feb 2002 B1
6357104 Myers Mar 2002 B1
6361555 Wilson Mar 2002 B1
6375676 Cox Apr 2002 B1
6379365 Diaz Apr 2002 B1
6383171 Gifford et al. May 2002 B1
6383215 Sass May 2002 B1
6398807 Chouinard et al. Jun 2002 B1
6409753 Brown et al. Jun 2002 B1
6415696 Erickson et al. Jul 2002 B1
6419693 Fariabi Jul 2002 B1
6428811 West et al. Aug 2002 B1
6443982 Israel et al. Sep 2002 B1
6451025 Jervis Sep 2002 B1
6451050 Rudakov et al. Sep 2002 B1
6464720 Boatman et al. Oct 2002 B2
6468298 Pelton Oct 2002 B1
6468299 Stack et al. Oct 2002 B2
6485510 Camrud et al. Nov 2002 B1
6485511 Lau et al. Nov 2002 B2
6488694 Lau et al. Dec 2002 B1
6488702 Besselink Dec 2002 B1
6488703 Kveen et al. Dec 2002 B1
6511468 Cragg et al. Jan 2003 B1
6514281 Blaeser et al. Feb 2003 B1
6520986 Martin et al. Feb 2003 B2
6520987 Plante Feb 2003 B1
6520988 Colombo et al. Feb 2003 B1
6527789 Lau et al. Mar 2003 B1
6527799 Shanley Mar 2003 B2
6529549 Norrell et al. Mar 2003 B1
6530944 West et al. Mar 2003 B2
6540777 Stenzel Apr 2003 B2
6540779 Richter et al. Apr 2003 B2
6551350 Thornton et al. Apr 2003 B1
6555157 Hossainy Apr 2003 B1
6569180 Sirhan et al. May 2003 B1
6575993 Yock Jun 2003 B1
6579305 Lashinski Jun 2003 B1
6579309 Loos et al. Jun 2003 B1
6582394 Reiss et al. Jun 2003 B1
6582460 Cryer Jun 2003 B1
6585756 Strecker Jul 2003 B1
6592549 Gerdts et al. Jul 2003 B2
6592568 Campbell Jul 2003 B2
6596020 Vardi et al. Jul 2003 B2
6596022 Lau et al. Jul 2003 B2
6599296 Gillick et al. Jul 2003 B1
6599314 Mathis Jul 2003 B2
6602282 Yan Aug 2003 B1
6605062 Hurley et al. Aug 2003 B1
6605109 Fiedler Aug 2003 B2
6607553 Healy et al. Aug 2003 B1
6645517 West et al. Nov 2003 B2
6645547 Shekalim et al. Nov 2003 B1
6656212 Ravenscroft et al. Dec 2003 B2
6660031 Tran et al. Dec 2003 B2
6660381 Halas et al. Dec 2003 B2
6666883 Seguin et al. Dec 2003 B1
6676695 Solem Jan 2004 B2
6679909 Mcintosh et al. Jan 2004 B2
6685721 Kramer Feb 2004 B1
6685730 West et al. Feb 2004 B2
6689156 Davidson et al. Feb 2004 B1
6692465 Kramer Feb 2004 B2
6692483 Vardi et al. Feb 2004 B2
6699280 Camrud et al. Mar 2004 B2
6699724 West Mar 2004 B1
6702843 Brown et al. Mar 2004 B1
6706062 Vardi et al. Mar 2004 B2
6709379 Brandau et al. Mar 2004 B1
6709440 Callol et al. Mar 2004 B2
6712827 Ellis et al. Mar 2004 B2
6712845 Hossainy Mar 2004 B2
6723071 Gerdts et al. Apr 2004 B2
6736842 Healy et al. May 2004 B2
6743251 Eder Jun 2004 B1
6749628 Callol et al. Jun 2004 B1
6761734 Suhr Jul 2004 B2
6770091 Richter et al. Aug 2004 B2
6778316 Halas et al. Aug 2004 B2
6800065 Duane et al. Oct 2004 B2
6811566 Penn et al. Nov 2004 B1
6825203 Pasternak et al. Nov 2004 B2
6835203 Vardi et al. Dec 2004 B1
6837901 Rabkin et al. Jan 2005 B2
6849084 Rabkin et al. Feb 2005 B2
6852252 Halas et al. Feb 2005 B2
6855125 Shanley Feb 2005 B2
6858034 Hijlkema et al. Feb 2005 B1
6875228 Pinchasik et al. Apr 2005 B2
6878161 Lenker Apr 2005 B2
6879370 Yokoue et al. Apr 2005 B2
6884258 Vardi et al. Apr 2005 B2
6893417 Gribbons et al. May 2005 B2
6896695 Mueller et al. May 2005 B2
6908477 Mcguckin, Jr. et al. Jun 2005 B2
6918928 Wolinsky et al. Jul 2005 B2
6939376 Shulze et al. Sep 2005 B2
6945989 Betelia et al. Sep 2005 B1
6945995 Nicholas Sep 2005 B2
6949120 Kveen et al. Sep 2005 B2
6951053 Padilla et al. Oct 2005 B2
6955687 Richter et al. Oct 2005 B2
6955688 Wilson et al. Oct 2005 B2
6962602 Vardi et al. Nov 2005 B2
6989026 Richter et al. Jan 2006 B2
7005454 Brocchini et al. Feb 2006 B2
7037327 Salmon et al. May 2006 B2
7052510 Richter May 2006 B1
7090694 Morris et al. Aug 2006 B1
7101840 Brocchini et al. Sep 2006 B2
7137993 Acosta et al. Nov 2006 B2
7147655 Chermoni Dec 2006 B2
7147656 Andreas et al. Dec 2006 B2
7182779 Acosta et al. Feb 2007 B2
7192440 Andreas et al. Mar 2007 B2
7220275 Davidson et al. May 2007 B2
7225518 Eidenschink et al. Jun 2007 B2
7241308 Andreas et al. Jul 2007 B2
7270668 Andreas et al. Sep 2007 B2
7294146 Chew et al. Nov 2007 B2
7300456 Andreas et al. Nov 2007 B2
7309350 Landreville et al. Dec 2007 B2
7314480 Eidenschink et al. Jan 2008 B2
7320702 Hammersmark et al. Jan 2008 B2
7323006 Andreas et al. Jan 2008 B2
7323009 Suhr et al. Jan 2008 B2
7326236 Andreas et al. Feb 2008 B2
7326242 Eidenschink Feb 2008 B2
7341598 Davidson et al. Mar 2008 B2
7344556 Seguin et al. Mar 2008 B2
7387639 Bourang et al. Jun 2008 B2
7445688 Suzuki et al. Nov 2008 B2
7520895 Douglas et al. Apr 2009 B2
7537609 Davidson et al. May 2009 B2
7540881 Meyer et al. Jun 2009 B2
7635383 Gumm Dec 2009 B2
7641684 Hilaire et al. Jan 2010 B2
7641685 Richter Jan 2010 B2
7686846 Laborde et al. Mar 2010 B2
7695508 Der Leest et al. Apr 2010 B2
7758634 Brucker et al. Jul 2010 B2
7799064 Brucker et al. Sep 2010 B2
8016870 Chew et al. Sep 2011 B2
8070789 Will et al. Dec 2011 B2
8206429 Gregorich et al. Jun 2012 B2
8769796 Bourang et al. Jul 2014 B2
8795347 Bourang et al. Aug 2014 B2
8808347 Bourang et al. Aug 2014 B2
8821562 Bourang et al. Sep 2014 B2
8828071 Bourang et al. Sep 2014 B2
8979917 Bourang et al. Mar 2015 B2
9254210 Bourang Feb 2016 B2
9364356 Bourang Jun 2016 B2
9724218 Bourang et al. Aug 2017 B2
9730821 Bourang et al. Aug 2017 B2
9737424 Bourang et al. Aug 2017 B2
9855158 Bourang et al. Jan 2018 B2
10219926 Bourang et al. Mar 2019 B2
10219927 Bourang et al. Mar 2019 B2
10610391 Bourang et al. Apr 2020 B2
10918506 Bourang et al. Feb 2021 B2
11000392 Bourang et al. May 2021 B2
11298252 Bourang et al. Apr 2022 B2
11426297 Bourang et al. Aug 2022 B2
20010003161 Vardi et al. Jun 2001 A1
20010020154 Bigus et al. Sep 2001 A1
20010020181 Layne Sep 2001 A1
20010039395 Mareiro et al. Nov 2001 A1
20010044595 Reydel et al. Nov 2001 A1
20010044622 Vardi et al. Nov 2001 A1
20010044632 Daniel et al. Nov 2001 A1
20010049547 Moore Dec 2001 A1
20020037358 Barry et al. Mar 2002 A1
20020091439 Baker et al. Jul 2002 A1
20020107560 Richter Aug 2002 A1
20020111671 Stenzel Aug 2002 A1
20020128706 Osypka Sep 2002 A1
20020138132 Brown Sep 2002 A1
20020143382 Hijlkema et al. Oct 2002 A1
20020151924 Shiber Oct 2002 A1
20020151955 Tran et al. Oct 2002 A1
20020156496 Chermoni Oct 2002 A1
20020173835 Bourang et al. Nov 2002 A1
20020177890 Lenker Nov 2002 A1
20020183763 Callol et al. Dec 2002 A1
20020188343 Mathis Dec 2002 A1
20020188347 Mathis Dec 2002 A1
20020193873 Brucker et al. Dec 2002 A1
20030028233 Vardi et al. Feb 2003 A1
20030029039 Richter et al. Feb 2003 A1
20030045923 Bashiri Mar 2003 A1
20030093143 Zhao et al. May 2003 A1
20030097169 Brucker et al. May 2003 A1
20030105922 Tomita Jun 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030114919 Mcquiston et al. Jun 2003 A1
20030114922 Iwasaka et al. Jun 2003 A1
20030125791 Sequin et al. Jul 2003 A1
20030125800 Shulze et al. Jul 2003 A1
20030125802 Callol et al. Jul 2003 A1
20030135259 Simso Jul 2003 A1
20030135266 Chew et al. Jul 2003 A1
20030139796 Sequin et al. Jul 2003 A1
20030139797 Johnson et al. Jul 2003 A1
20030139798 Brown et al. Jul 2003 A1
20030163085 Tanner et al. Aug 2003 A1
20030176909 Kusleika Sep 2003 A1
20030191516 Weldon et al. Oct 2003 A1
20030192164 Austin Oct 2003 A1
20030195609 Berenstein et al. Oct 2003 A1
20030199821 Gerdts et al. Oct 2003 A1
20030204238 Tedeschi Oct 2003 A1
20030212447 Euteneuer et al. Nov 2003 A1
20030225446 Hartley Dec 2003 A1
20040024450 Shulze et al. Feb 2004 A1
20040030380 Shulze et al. Feb 2004 A1
20040044395 Nelson Mar 2004 A1
20040044398 Nicholas Mar 2004 A1
20040085845 Ooishi May 2004 A1
20040087965 Levine et al. May 2004 A1
20040093061 Acosta et al. May 2004 A1
20040093067 Israel May 2004 A1
20040093077 White et al. May 2004 A1
20040098081 Landreville et al. May 2004 A1
20040106979 Goicoechea et al. Jun 2004 A1
20040111145 Serino et al. Jun 2004 A1
20040117008 Wnendt et al. Jun 2004 A1
20040138732 Suhr et al. Jul 2004 A1
20040176832 Hartley et al. Sep 2004 A1
20040186551 Kao et al. Sep 2004 A1
20040193245 Deem et al. Sep 2004 A1
20040215165 Coyle et al. Oct 2004 A1
20040215312 Andreas Oct 2004 A1
20040243217 Andersen et al. Dec 2004 A1
20040249434 Andreas et al. Dec 2004 A1
20040249435 Andreas et al. Dec 2004 A1
20050010276 Acosta et al. Jan 2005 A1
20050038505 Shulze et al. Feb 2005 A1
20050049673 Andreas et al. Mar 2005 A1
20050049680 Fischell et al. Mar 2005 A1
20050080474 Andreas et al. Apr 2005 A1
20050080475 Andreas et al. Apr 2005 A1
20050085845 Hilaire et al. Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050101624 Betts et al. May 2005 A1
20050119731 Brucker et al. Jun 2005 A1
20050125051 Eidenschink et al. Jun 2005 A1
20050131008 Betts et al. Jun 2005 A1
20050133164 Fischer et al. Jun 2005 A1
20050143827 Globerman et al. Jun 2005 A1
20050149159 Andreas et al. Jul 2005 A1
20050165378 Heinrich et al. Jul 2005 A1
20050182473 Eidenschink et al. Aug 2005 A1
20050183259 Eidenschink et al. Aug 2005 A1
20050197688 Theron et al. Sep 2005 A1
20050209674 Kutscher et al. Sep 2005 A1
20050222671 Schaeffer et al. Oct 2005 A1
20050228477 Grainger et al. Oct 2005 A1
20050245637 Hossainy et al. Nov 2005 A1
20050245941 Vardi et al. Nov 2005 A1
20050288763 Andreas et al. Dec 2005 A1
20050288764 Snow et al. Dec 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060069424 Acosta et al. Mar 2006 A1
20060100694 Globerman May 2006 A1
20060116748 Kaplan et al. Jun 2006 A1
20060123874 Motsenbocker Jun 2006 A1
20060155362 Israel Jul 2006 A1
20060200223 Andreas et al. Sep 2006 A1
20060206190 Chermoni Sep 2006 A1
20060229700 Acosta et al. Oct 2006 A1
20060229706 Shulze et al. Oct 2006 A1
20060271090 Shaked et al. Nov 2006 A1
20060271150 Andreas et al. Nov 2006 A1
20060271151 Mcgarry et al. Nov 2006 A1
20060271152 Hilaire et al. Nov 2006 A1
20060282147 Andreas Dec 2006 A1
20060282149 Kao Dec 2006 A1
20060282150 Olson et al. Dec 2006 A1
20060287726 Segal et al. Dec 2006 A1
20070027521 Andreas et al. Feb 2007 A1
20070027524 Johnson et al. Feb 2007 A1
20070055351 Eidenschink et al. Mar 2007 A1
20070061003 Shmulewitz et al. Mar 2007 A1
20070067012 George et al. Mar 2007 A1
20070088368 Acosta et al. Apr 2007 A1
20070088420 Andreas et al. Apr 2007 A1
20070088422 Chew et al. Apr 2007 A1
20070100423 Acosta et al. May 2007 A1
20070100424 Chew et al. May 2007 A1
20070106365 Andreas et al. May 2007 A1
20070118202 Chermoni May 2007 A1
20070118203 Chermoni May 2007 A1
20070118204 Chermoni May 2007 A1
20070123970 Lenz May 2007 A1
20070129733 Will et al. Jun 2007 A1
20070156225 George et al. Jul 2007 A1
20070156226 Chew et al. Jul 2007 A1
20070179587 Acosta et al. Aug 2007 A1
20070203571 Kaplan et al. Aug 2007 A1
20070219611 Krever et al. Sep 2007 A1
20070219612 Andreas et al. Sep 2007 A1
20070219613 Kao et al. Sep 2007 A1
20070219625 Venturelli et al. Sep 2007 A1
20070264305 Von et al. Nov 2007 A1
20070265637 Andreas et al. Nov 2007 A1
20070270936 Andreas et al. Nov 2007 A1
20070276460 Davis et al. Nov 2007 A1
20070276461 Andreas et al. Nov 2007 A1
20070281117 Kaplan et al. Dec 2007 A1
20070282419 Hilaire et al. Dec 2007 A1
20070292518 Ludwig Dec 2007 A1
20080009932 Ta et al. Jan 2008 A1
20080009933 Ta et al. Jan 2008 A1
20080051869 Yribarren Feb 2008 A1
20080071345 Hammersmark et al. Mar 2008 A1
20080077229 Andreas et al. Mar 2008 A1
20080091257 Andreas et al. Apr 2008 A1
20080097299 Andreas et al. Apr 2008 A1
20080097574 Andreas et al. Apr 2008 A1
20080132989 Snow et al. Jun 2008 A1
20080147162 Andreas et al. Jun 2008 A1
20080199510 Ruane et al. Aug 2008 A1
20080208309 Saeed Aug 2008 A1
20080208311 Kao et al. Aug 2008 A1
20080208318 Kao et al. Aug 2008 A1
20080221655 Miller Sep 2008 A1
20080234795 Snow et al. Sep 2008 A1
20080234798 Chew et al. Sep 2008 A1
20080234799 Acosta et al. Sep 2008 A1
20080269865 Snow et al. Oct 2008 A1
20090048655 Jang Feb 2009 A1
20090076584 Mao et al. Mar 2009 A1
20090105686 Snow et al. Apr 2009 A1
20090132019 Duffy et al. May 2009 A1
20090143854 Adams et al. Jun 2009 A1
20090171430 Baim et al. Jul 2009 A1
20090182270 Nanavati Jul 2009 A1
20090182409 Feld et al. Jul 2009 A1
20090228088 Lowe et al. Sep 2009 A1
20090240321 Davidson et al. Sep 2009 A1
20090254167 Ricci et al. Oct 2009 A1
20090259285 Duane et al. Oct 2009 A1
20090287289 Sagedahl et al. Nov 2009 A1
20090299454 Jennings et al. Dec 2009 A1
20090319030 Yadin et al. Dec 2009 A1
20090326641 Davis et al. Dec 2009 A1
20100004737 Eidenschink Jan 2010 A1
20100030183 Toner et al. Feb 2010 A1
20100036477 Bronson et al. Feb 2010 A1
20100042199 Burton Feb 2010 A1
20100049298 Hamer et al. Feb 2010 A1
20100057020 Uretsky Mar 2010 A1
20100063571 Roach et al. Mar 2010 A1
20100106238 Hilaire et al. Apr 2010 A1
20100222861 Dibie Sep 2010 A1
20110029061 Ahn et al. Feb 2011 A1
20110282427 Bourang et al. Nov 2011 A1
20110307044 Bourang et al. Dec 2011 A1
20110307045 Bourang et al. Dec 2011 A1
20110307046 Bourang et al. Dec 2011 A1
20110307047 Bourang et al. Dec 2011 A1
20110307052 Bourang et al. Dec 2011 A1
20130268047 Bourang Oct 2013 A1
20140100647 Bourang Apr 2014 A1
20150032196 Bourang et al. Jan 2015 A1
20150073521 Bourang et al. Mar 2015 A1
20150073527 Bourang et al. Mar 2015 A1
20150081001 Bourang et al. Mar 2015 A1
20150081002 Bourang et al. Mar 2015 A1
20150216690 Bourang et al. Aug 2015 A1
20160100966 Bourang Apr 2016 A1
20160256303 Bourang Sep 2016 A1
20170319366 Bourang et al. Nov 2017 A1
20180085239 Bourang et al. Mar 2018 A1
20190151126 Bourang et al. May 2019 A1
20190151127 Bourang et al. May 2019 A1
20200188150 Bourang et al. Jun 2020 A1
20210121310 Bourang et al. Apr 2021 A1
20220265451 Bourang et al. Aug 2022 A1
20220346990 Bourang et al. Nov 2022 A1
Foreign Referenced Citations (119)
Number Date Country
2011232357 Oct 2012 AU
2011232361 Oct 2012 AU
2011232362 Oct 2012 AU
2011232361 May 2015 AU
2011232357 Oct 2015 AU
2011232362 Dec 2015 AU
2794078 Sep 2011 CA
2794288 Sep 2011 CA
1441654 Sep 2003 CN
1788977 Jun 2006 CN
1867374 Nov 2006 CN
101035488 Sep 2007 CN
101151001 Mar 2008 CN
102215780 Oct 2011 CN
103037813 Apr 2013 CN
103037815 Apr 2013 CN
103037816 Apr 2013 CN
103037817 Apr 2013 CN
103068345 Apr 2013 CN
103037816 Dec 2018 CN
109363807 Feb 2019 CN
0203945 Dec 1986 EP
0274129 Jul 1988 EP
0282143 Sep 1988 EP
0274129 May 1992 EP
0505686 Sep 1992 EP
0533960 Mar 1993 EP
0596145 May 1994 EP
0714640 Jun 1996 EP
0203945 Jun 1998 EP
0897700 Feb 1999 EP
0947180 Oct 1999 EP
1074227 Feb 2001 EP
1258230 Nov 2002 EP
1266638 Dec 2002 EP
1277449 Jan 2003 EP
1523959 Apr 2005 EP
1523960 Apr 2005 EP
1266638 Oct 2005 EP
1788977 May 2007 EP
1867374 Dec 2007 EP
1788977 Mar 2008 EP
1905398 Apr 2008 EP
2036519 Mar 2009 EP
2344068 Jul 2011 EP
2549949 Jan 2013 EP
2549950 Jan 2013 EP
2549951 Jan 2013 EP
2549952 Jan 2013 EP
2549958 Jan 2013 EP
2672925 Dec 2013 EP
2672932 Dec 2013 EP
2549951 May 2017 EP
2549949 Nov 2019 EP
2733689 Nov 1996 FR
1043313 Feb 1998 JP
2003532437 Nov 2003 JP
2004052887 Feb 2004 JP
2004528877 Sep 2004 JP
2007508082 Apr 2007 JP
2010503465 Feb 2010 JP
2012503534 Feb 2012 JP
2013523215 Jun 2013 JP
WO-9013332 Nov 1990 WO
WO-9112779 Sep 1991 WO
WO-9626689 Sep 1996 WO
WO-9633677 Oct 1996 WO
WO-9746174 Dec 1997 WO
WO-9748351 Dec 1997 WO
WO-9820810 May 1998 WO
WO-9837833 Sep 1998 WO
WO-9858600 Dec 1998 WO
WO-9901087 Jan 1999 WO
WO-0012832 Mar 2000 WO
WO-0015151 Mar 2000 WO
WO-0025841 May 2000 WO
WO-0012832 Jun 2000 WO
WO-0032136 Jun 2000 WO
WO-0041649 Jul 2000 WO
WO-0050116 Aug 2000 WO
WO-0062708 Oct 2000 WO
WO-0072780 Dec 2000 WO
WO-0074595 Dec 2000 WO
WO-0170297 Sep 2001 WO
WO-0191918 Dec 2001 WO
WO-02060344 Aug 2002 WO
WO-02085253 Oct 2002 WO
WO-03022178 Mar 2003 WO
WO-03047651 Jun 2003 WO
WO-03051425 Jun 2003 WO
WO-03055414 Jul 2003 WO
WO-03105922 Dec 2003 WO
WO-2004017865 Mar 2004 WO
WO-2004043299 May 2004 WO
WO-2004043301 May 2004 WO
WO-2004043510 May 2004 WO
WO-2004052237 Jun 2004 WO
WO-2005013853 Feb 2005 WO
WO-2005039681 May 2005 WO
WO-2006036939 Apr 2006 WO
WO-2006047520 May 2006 WO
WO-2007035805 Mar 2007 WO
WO-2007053187 May 2007 WO
WO-2007146411 Dec 2007 WO
WO-2008005111 Jan 2008 WO
WO-2008033621 Mar 2008 WO
WO-2008130503 Oct 2008 WO
WO-2009148594 Dec 2009 WO
WO-2009148997 Dec 2009 WO
WO-2010022516 Mar 2010 WO
WO-2010036982 Apr 2010 WO
WO-2011119879 Sep 2011 WO
WO-2011119880 Sep 2011 WO
WO-2011119882 Sep 2011 WO
WO-2011119883 Sep 2011 WO
WO-2011119884 Sep 2011 WO
WO-2012109365 Aug 2012 WO
WO-2012109382 Aug 2012 WO
WO-2012109382 Jan 2013 WO
Non-Patent Literature Citations (245)
Entry
U.S. Appl. No. 17/143,015, filed Jan. 6, 2021, System and Methods for Treating a Bifurcation.
U.S. Appl. No. 16/251,767, filed Jan. 18, 2019, Selective Stent Crimping.
U.S. Appl. No. 16/800,905, filed Feb. 25, 2020, Stent Alignment During Treatment of a Bifurcation.
“U.S. Appl. No. 16/251,767, Notice of Allowance dated Apr. 20, 2022”, 7 pgs.
“U.S. Appl. No. 17/690,774, Preliminary Amendment filed Nov. 16, 2022”, 7 pgs.
“U.S. Appl. No. 17/869,399, Preliminary Amendment filed Jul. 25, 2022”, 3 pgs.
“U.S. Appl. No. 17/869,399, Preliminary Amendment filed Nov. 9, 2022”, 6 pgs.
“U.S. Appl. No. 16/251,767, Notice of Non-Compliant Amendment dated Aug. 25, 2021”, 3 pgs.
“U.S. Appl. No. 16/251,767, Response filed Oct. 6, 2021 to Notice of Non-Compliant Amendment dated Aug. 25, 2021”, 8 pgs.
“European Application Serial No. 09816963.4, Response filed Oct. 11, 2021 to Communication Pursuant to Article 94(3) EPC dated May 31, 2021”, 14 pgs.
“U.S. Appl. No. 16/251,767, Non Final Office Action dated Nov. 15, 2021”, 11 pgs.
“U.S. Appl. No. 16/800,905, Notice of Allowance dated Dec. 8, 2021”, 14 pgs.
“U.S. Appl. No. 16/251,767, Response filed Feb. 14, 2022 to Non Final Office Action dated Nov. 15, 2021”, 5 pgs.
“U.S. Appl. No. 13/071,149, 312 Amendment filed May 29, 2014”, 3 pgs.
“U.S. Appl. No. 13/071,149, Final Office Action dated Nov. 5, 2013”, 20 pgs.
“U.S. Appl. No. 13/071,149, Non Final Office Action dated Apr. 11, 2013”, 16 pgs.
“U.S. Appl. No. 13/071,149, Notice of Allowance dated Mar. 26, 2014”, 11 pgs.
“U.S. Appl. No. 13/071,149, PTO Response to Rule 312 Communication dated Jul. 14, 2014”, 2 pgs.
“U.S. Appl. No. 13/071,149, Response filed Feb. 3, 2014 to Final Office Action dated Nov. 5, 2013”, 9 pgs.
“U.S. Appl. No. 13/071,149, Response filed Feb. 26, 2013 to Restriction Requirement dated Jan. 30, 2013”, 2 pgs.
“U.S. Appl. No. 13/071,149, Response filed Oct. 3, 2013 to Non Final Office Action dated Apr. 11, 2013”, 16 pgs.
“U.S. Appl. No. 13/071,149, Restriction Requirement dated Jan. 30, 2013”, 7 pgs.
“U.S. Appl. No. 13/071,162, 312 Amendment filed May 29, 2014”, 3 pgs.
“U.S. Appl. No. 13/071,162, 312 Amendment filed Aug. 7, 2014”, 3 pgs.
“U.S. Appl. No. 13/071,162, Examiner Interview Summary dated Feb. 6, 2014”, 3 pgs.
“U.S. Appl. No. 13/071,162, Non Final Office Action dated Aug. 30, 2013”, 17 pgs.
“U.S. Appl. No. 13/071,162, Notice of Allowance dated Mar. 31, 2014”, 12 pgs.
“U.S. Appl. No. 13/071,162, PTO Response to Rule 312 Communication dated Jul. 22, 2014”, 3 pgs.
“U.S. Appl. No. 13/071,162, PTO Response to Rule 312 Communication dated Aug. 12, 2014”, 2 pgs.
“U.S. Appl. No. 13/071,162, Response filed Jan. 30, 2014 to Non Final Office Action dated Aug. 30, 2013”, 12 pgs.
“U.S. Appl. No. 13/071,162, Response filed Jul. 11, 2013 to Restriction Requirement dated Apr. 11, 2013”, 1 pg.
“U.S. Appl. No. 13/071,162, Restriction Requirement dated Apr. 11, 2013”, 7 pgs.
“U.S. Appl. No. 13/071,183, 312 Amendment filed May 29, 2014”, 3 pgs.
“U.S. Appl. No. 13/071,183, Examiner Interview Summary dated Feb. 6, 2014”, 3 pgs.
“U.S. Appl. No. 13/071,183, Final Office Action dated Nov. 5, 2013”, 35 pgs.
“U.S. Appl. No. 13/071,183, Non Final Office Action dated Mar. 29, 2013”, 23 pgs.
“U.S. Appl. No. 13/071,183, Notice of Allowance dated Mar. 20, 2014”, 13 pgs.
“U.S. Appl. No. 13/071,183, PTO Response to Rule 312 Communication dated Jul. 22, 2014”, 3 pgs.
“U.S. Appl. No. 13/071,183, Response filed Feb. 5, 2014 to Final Office Action dated Nov. 5, 2013”, 14 pgs.
“U.S. Appl. No. 13/071,183, Response filed Aug. 5, 2013 to Non Final Office Action dated Mar. 29, 2013”, 20 pgs.
“U.S. Appl. No. 13/071,183, Response filed Oct. 15, 2012 to Restriction Requirement dated Sep. 13, 2012”, 1 pg.
“U.S. Appl. No. 13/071,183, Restriction Requirement dated Sep. 13, 2012”, 7 pgs.
“U.S. Appl. No. 13/071,198, 312 Amendment filed May 29, 2014”, 7 pgs.
“U.S. Appl. No. 13/071,198, 312 Amendment filed Jun. 24, 2014”, 3 pgs.
“U.S. Appl. No. 13/071,198, Examiner Interview Summary dated Feb. 5, 2014”, 3 pgs.
“U.S. Appl. No. 13/071,198, Final Office Action dated Nov. 6, 2013”, 20 pgs.
“U.S. Appl. No. 13/071,198, Non Final Office Action dated Apr. 11, 2013”, 17 pgs.
“U.S. Appl. No. 13/071,198, Notice of Allowance dated Mar. 24, 2014”, 11 pgs.
“U.S. Appl. No. 13/071,198, PTO Response to Rule 312 Communication dated Jun. 27, 2014”. 2 pgs.
“U.S. Appl. No. 13/071,198, PTO Response to Rule 312 Communication dated Jul. 3, 2014”, 3 pgs.
“U.S. Appl. No. 13/071,198, Response filed Feb. 6, 2014 to Final Office Action dated Nov. 6, 2013”, 10 pgs.
“U.S. Appl. No. 13/071,198, Response filed Oct. 10, 2013 to Non Final Office Action dated Apr. 11, 2013”, 11 pgs.
“U.S. Appl. No. 13/071,198, Response filed Nov. 12, 2012 to Restriction Requirement dated Oct. 16, 2012”, 2 pgs.
“U.S. Appl. No. 13/071,198, Restriction Requirement dated Oct. 16, 2012”, 7 pgs.
“U.S. Appl. No. 13/071,239, Examiner Interview Summary dated Feb. 5, 2014”, 4 pgs.
“U.S. Appl. No. 13/071,239, Final Office Action dated Nov. 26, 2013”, 18 pgs.
“U.S. Appl. No. 13/071,239, Non Final Office Action dated Mar. 14, 2013”, 17 pgs.
“U.S. Appl. No. 13/071,239, Notice of Allowance dated Mar. 4, 2014”, 10 pgs.
“U.S. Appl. No. 13/071,239, PTO Response to 312 Communication dated Jun. 9, 2014”, 2 pgs.
“U.S. Appl. No. 13/071,239, Response filed Feb. 6, 2014 to Final Office Action dated Nov. 26, 2013”, 8 pgs.
“U.S. Appl. No. 13/071,239, Response filed Sep. 16, 2013 to Non Final Office Action dated Mar. 14, 2013”, 9 pgs.
“U.S. Appl. No. 13/071,239, Response filed Nov. 12, 2012 to Restriction Requirement dated Oct. 12, 2012”, 2 pgs.
“U.S. Appl. No. 13/071,239, Restriction Requirement dated Oct. 12, 2012”, 8 pgs.
“U.S. Appl. No. 13/071,251, Non Final Office Action dated Sep. 10, 2013”, 15 pgs.
“U.S. Appl. No. 13/071,251, Notice of Allowance dated May 28, 2014”, 15 pgs.
“U.S. Appl. No. 13/071,251, Notice of Allowance dated Aug. 13, 2014”, 12 pgs.
“U.S. Appl. No. 13/796,424, Notice of Allowance dated Feb. 16, 2016”, 13 pgs.
“U.S. Appl. No. 13/796,466, Non Final Office Action dated Apr. 3, 2015”, 19 pgs.
“U.S. Appl. No. 13/796,466, Notice of Allowance dated Oct. 7, 2015”, 16 pgs.
“U.S. Appl. No. 13/796,466, Notice of Allowance dated Nov. 18, 2015”, 2 pgs.
“U.S. Appl. No. 14/294,631, Examiner Interview Summary dated Feb. 8, 2017”, 3 pgs.
“U.S. Appl. No. 14/294,631, Examiner Interview Summary dated Apr. 11, 2018”, 4 pgs.
“U.S. Appl. No. 14/294,631, Final Office Action dated Mar. 24, 2017”, 15 pgs.
“U.S. Appl. No. 14/294,631, Non Final Office Action dated Sep. 22, 2017”, 16 pgs.
“U.S. Appl. No. 14/294,631, Non Final Office Action dated Oct. 7, 2016”, 15 pgs.
“U.S. Appl. No. 14/294,631, Notice of Allowance dated Jul. 17, 2018”, 9 pgs.
“U.S. Appl. No. 14/294,631, Notice of Allowance dated Nov. 16, 2018”, 8 pgs.
“U.S. Appl. No. 14/294,631, Response filed Feb. 7, 2017 to Non Final Office Action dated Oct. 7, 2016”, 10 pgs.
“U.S. Appl. No. 14/294,631, Response filed Mar. 21, 2018 to Non Final Office Action dated Sep. 22, 2017”, 8 pgs.
“U.S. Appl. No. 14/294,631, Response filed Jul. 24, 2017 to Final Office Action dated Mar. 24, 2017”, 8 pgs.
“U.S. Appl. No. 14/313,742, Examiner Interview Summary dated Jul. 14, 2017”, 4 pgs.
“U.S. Appl. No. 14/313,742, Examiner Interview Summary dated Dec. 7, 2016”, 3 pgs.
“U.S. Appl. No. 14/313,742, Final Office Action dated Aug. 12, 2016”, 19 pgs.
“U.S. Appl. No. 14/313,742, Non Final Office Action dated Jan. 29, 2016”, 17 pgs.
“U.S. Appl. No. 14/313,742, Non Final Office Action dated Mar. 24, 2017”, 20 pgs.
“U.S. Appl. No. 14/313,742, Notice of Allowance dated Oct. 20, 2017”, 8 pgs.
“U.S. Appl. No. 14/313,742, Response filed Apr. 29, 2016 to Non Final Office Action dated Jan. 29, 2016”, 10 pgs.
“U.S. Appl. No. 14/313,742, Response filed Jul. 24, 2017 to Non Final Office Action dated Mar. 24, 2017”, 12 pgs.
“U.S. Appl. No. 14/313,742, Response filed Dec. 12, 2016 to Final Office Action dated Aug. 12, 2016”, 10 pgs.
“U.S. Appl. No. 14/314,361, Examiner Interview Summary dated Feb. 8, 2017”, 3 pgs.
“U.S. Appl. No. 14/314,361, Examiner Interview Summary dated Mar. 24, 2017”, 2 pgs.
“U.S. Appl. No. 14/314,361, Non Final Office Action dated Oct. 6, 2016”, 33 pgs.
“U.S. Appl. No. 14/314,361, Notice of Allowance dated Apr. 12, 2017”, 11 pgs.
“U.S. Appl. No. 14/314,361, Response filed Feb. 6, 2017 to Non Final Office Action dated Oct. 6, 2016”, 17 pgs.
“U.S. Appl. No. 14/317,387, Examiner Interview Summary dated Feb. 9, 2017”, 3 pgs.
“U.S. Appl. No. 14/317,387, Examiner Interview Summary dated Mar. 24, 2017”, 2 pgs.
“U.S. Appl. No. 14/317,387, Non Final Office Action dated Oct. 6, 2016”, 15 pgs.
“U.S. Appl. No. 14/317,387, Notice of Allowance dated Apr. 17, 2017”, 10 pgs.
“U.S. Appl. No. 14/317,387, Response filed Feb. 6, 2017 to Non Final Office Action dated Oct. 6, 2016”, 14 pgs.
“U.S. Appl. No. 14/321,506, Examiner Interview Summary dated Feb. 8, 2017”, 3 pgs.
“U.S. Appl. No. 14/321,506, Examiner Interview Summary dated Mar. 24, 2017”, 2 pgs.
“U.S. Appl. No. 14/321,506, Non Final Office Action dated Oct. 6, 2016”, 15 pgs.
“U.S. Appl. No. 14/321,506, Notice of Allowance dated Apr. 4, 2017”, 10 pgs.
“U.S. Appl. No. 14/321,506, Response filed Feb. 6, 2017 to Non Final Office Action dated Oct. 6, 2016”, 12 pgs.
“U.S. Appl. No. 14/621,231, Examiner Interview Summary dated May 8, 2018”, 4 pgs.
“U.S. Appl. No. 14/621,231, Final Office Action dated Oct. 20, 2017”, 19 pgs.
“U.S. Appl. No. 14/621,231, Non Final Office Action dated Jun. 15, 2017”, 17 pgs.
“U.S. Appl. No. 14/621,231, Notice of Allowance dated Jul. 31, 2018”, 11 pgs.
“U.S. Appl. No. 14/621,231, Notice of Allowance dated Nov. 16, 2018”, 8 pgs.
“U.S. Appl. No. 14/621,231, Preliminary Amendment filed Apr. 27, 2015”, 3 pgs.
“U.S. Appl. No. 14/621,231, Preliminary Amendment filed May 26, 2015”, 6 pgs.
“U.S. Appl. No. 14/621,231, Response filed Apr. 19, 2018 to Final Office Action dated Oct. 20, 2017”, 9 pgs.
“U.S. Appl. No. 14/621,231, Response filed May 22, 2017 to Restriction Requirement dated Mar. 21, 2017”, 1 pg.
“U.S. Appl. No. 14/621,231, Response filed Sep. 14, 2017 to Non Final Office Action dated Jun. 15, 2017”, 9 pgs.
“U.S. Appl. No. 14/621,231, Restriction Requirement dated Mar. 21, 2017”, 8 pgs.
“U.S. Appl. No. 14/621,231, Supplemental Amendment filed Jun. 1, 2018”, 8 pgs.
“U.S. Appl. No. 15/157,321, Non Final Office Action dated Aug. 11, 2017”, 10 pgs.
“U.S. Appl. No. 15/661,975, Final Office Action dated Jul. 20, 2020”, 10 pgs.
“U.S. Appl. No. 15/661,975, Non Final Office Action dated Feb. 27, 2020”, 12 pgs.
“U.S. Appl. No. 15/661,975, Non Final Office Action dated Oct. 28, 2020”, 14 pgs.
“U.S. Appl. No. 15/661,975, Notice of Allowance dated Mar. 24, 2021”, 8 pgs.
“U.S. Appl. No. 15/661,975, Response filed Jan. 27, 2021 to Non Final Office Action dated Oct. 28, 2020”, 6 pgs.
“U.S. Appl. No. 15/661,975, Response filed May 26, 2020 to Non Final Office Action dated Feb. 27, 2020”, 6 pgs.
“U.S. Appl. No. 15/661,975, Response filed Sep. 25, 2020 to Final Office Action dated Jul. 20, 2020”, 6 pgs.
“U.S. Appl. No. 15/661,975, Response Filed Nov. 21, 2019 to Restriction Requirement dated Sep. 24, 2019”, 8 pgs.
“U.S. Appl. No. 15/661,975, Restriction Requirement dated Sep. 24, 2019”, 6 pgs.
“U.S. Appl. No. 15/831,110, Non Final Office Action dated Oct. 18, 2019”, 18 pgs.
“U.S. Appl. No. 15/831,110, Notice of Allowance dated Feb. 6, 2020”, 9 pgs.
“U.S. Appl. No. 15/831,110, Preliminary Amendment filed Apr. 18, 2018”, 5 pgs.
“U.S. Appl. No. 15/831,110, Response filed Jan. 20, 2020 to Non Final Office Action dated Oct. 18, 2019”, 8 pgs.
“U.S. Appl. No. 16/251,691, Non Final Office Action dated Aug. 7, 2020”, 15 pgs.
“U.S. Appl. No. 16/251,691, Notice of Allowance dated Oct. 15, 2020”, 9 pgs.
“U.S. Appl. No. 16/251,691, Preliminary Amendment filed Jan. 21, 2019”, 3 pgs.
“U.S. Appl. No. 16/251,691, Response filed Sep. 30, 2020 to Non Final Office Action dated Aug. 7, 2020”, 7 pgs.
“U.S. Appl. No. 16/251,691, Supplemental Notice of Allowability dated Jan. 6, 2021”, 2 pgs.
“U.S. Appl. No. 16/251,691, Supplemental Notice of Allowability dated Nov. 24, 2020”, 2 pgs.
“U.S. Appl. No. 16/251,767, Non Final Office Action dated Oct. 9, 2020”, 9 pgs.
“U.S. Appl. No. 16/251,767, Non Final Office Action dated Oct. 20, 2020”, 10 pgs.
“U.S. Appl. No. 16/251,767, Preliminary Amendment filed Jan. 21, 2019”, 3 pgs.
“U.S. Appl. No. 16/251,767, Response filed Jan. 19, 2021 to Non Final Office Action dated Oct. 20, 2020”, 6 pgs.
“Australian Application Serial No. 2011232357, First Examination Report dated Dec. 3, 2014”, 2 pgs.
“Australian Application Serial No. 2011232358, First Examination Report dated Dec. 5, 2014”, 2 pgs.
“Australian Application Serial No. 2011232360, First Examination Report dated Dec. 9, 2014”, 2 pgs.
“Australian Application Serial No. 2011232361, First Examination Report dated Dec. 12, 2014”, 3 pgs.
“Australian Application Serial No. 2011232362, First Examination Report dated Jan. 11, 2015”, 2 pgs.
“Chinese Application Serial No. 200980143592.X, Final Office Action dated Jun. 4, 2013”, 10 pgs.
“Chinese Application Serial No. 200980143592.X, Office Action dated Apr. 21, 2014”, w/ English Translation, 18 pgs.
“Chinese Application Serial No. 200980143592.X, Office Action dated Jun. 4, 2013”, 10 pgs.
“Chinese Application Serial No. 2009801473592.X, Office Action dated Nov. 24, 2014”, 16 pgs.
“Chinese Application Serial No. 201180025662.9, Office Action dated Aug. 21, 2014”, 25 pgs.
“Chinese Application Serial No. 201180025670.3, Office Action dated Aug. 20, 2014”, 24 pgs.
“Chinese Application Serial No. 201180025716.1, Office Action dated Aug. 22, 2014”, 28 pgs.
“Chinese Application Serial No. 201180025742.4, Office Action dated Oct. 29, 2014”, 12 pgs.
“Chinese Application Serial No. 201180025746.2, Office Action dated Sep. 28, 2014”, 21 pgs.
“Drug Delivery Stent With Holes Located on Neutral Axis”, No. 429007; Research Disclosure, Kenneth Mason Publications, Hampshire, CB vol. 2266, (Jan. 2000), 13 pgs.
“European Application Serial No. 05727731.1, Supplementary European Search Report dated Apr. 8, 2008”, 3 pgs.
“European Application Serial No. 05744136.2, Supplementary European Search Report dated Apr. 9, 2008”, 3 pgs.
“European Application Serial No. 09816963.4, Extended European Search Report dated Aug. 21, 2015”, 5 pgs.
“European Application Serial No. 11760253.2, Extended European Search Report dated Feb. 22, 2017”, 7 pgs.
“European Application Serial No. 11760254.0, Extended European Search Report dated Apr. 12, 2017”, 6 pgs.
“European Application Serial No. 11760256.5, Extended European Search Report dated Aug. 12, 2016”, 8 pgs.
“European Application Serial No. 11760257.3, Extended European Search Report dated Sep. 29, 2015”, 7 pgs.
“European Application Serial No. 11760258.1, Extended European Search Report dated Dec. 5, 2016”, 8 pgs.
“European Application Serial No. 12744749.8, Extended European Search Report dated Apr. 7, 2016”, 10 pgs.
“European Application Serial No. 12744813.2, Extended European Search Report dated Nov. 25, 2015”, 9 pgs.
“Functional Sites on Non-polymeric Materials: Gas Plasma Treatment and Surface Analysis”, Evans Analytical Group, [Online] Retrieved from the internet: <URL: http://www.eaglabs.com>, (2003), 2 pgs.
“International Application Serial No. PCT/US11/29859, International Search Report dated May 23, 2011”, 2 pgs.
“International Application Serial No. PCT/US11/29859, Written Opinion dated May 23, 2011”, 6 pgs.
“International Application Serial No. PCT/US11/29861, International Search Report dated May 20, 2011”, 2 pgs.
“International Application Serial No. PCT/US11/29861, Written Opinion dated May 20, 2011”, 7 pgs.
“International Application Serial No. PCT/US2009/058505, International Preliminary Report on Patentability dated Oct. 28, 2010”, 11 pgs.
“International Application Serial No. PCT/US2009/058505, International Search Report dated Nov. 25, 2009”, 2 pgs.
“International Application Serial No. PCT/US2009/058505, Written Opinion dated Nov. 25, 2009”, 9 pgs.
“International Application Serial No. PCT/US2011/029858, International Search Report dated May 25, 2011”, 2 pgs.
“International Application Serial No. PCT/US2011/029858, Written Opinion dated May 25, 2011”, 7 pgs.
“International Application Serial No. PCT/US2011/029859, International Preliminary Report on Patentability dated Oct. 4, 2012”, 8 pgs.
“International Application Serial No. PCT/US2011/029859, International Search Report dated May 23, 2011”, 2 pgs.
“International Application Serial No. PCT/US2011/029859, Written Opinion dated May 23, 2011”, 6 pgs.
“International Application Serial No. PCT/US2011/029861, International Preliminary Report on Patentability dated Oct. 4, 2012”, 9 pgs.
“International Application Serial No. PCT/US2011/029861, International Search Report dated May 20, 2011”, 2 pgs.
“International Application Serial No. PCT/US2011/029861, Written Opinion dated May 20, 2011”, 7 pgs.
“International Application Serial No. PCT/US2011/029862, International Preliminary Report on Patentability dated Oct. 4, 2012”, 11 pgs.
“International Application Serial No. PCT/US2011/029862, International Search Report dated May 25, 2011”, 2 pgs.
“International Application Serial No. PCT/US2011/029862, Written Opinion dated May 25, 2011”, 9 pgs.
“International Application Serial No. PCT/US2011/029863, International Preliminary Report on Patentability dated Oct. 4, 2012”, 13 pgs.
“International Application Serial No. PCT/US2011/029863, International Search Report dated May 27, 2011”, 2 pgs.
“International Application Serial No. PCT/US2011/029863, Written Opinion dated May 27, 2011”, 11 pgs.
“International Application Serial No. PCT/US2012/024347, International Preliminary Report on Patentability dated Aug. 22, 2013”, 9 pgs.
“International Application Serial No. PCT/US2012/024347, International Search Report dated Jun. 29, 2012”, 2 pgs.
“International Application Serial No. PCT/US2012/024347, Written Opinion dated Jun. 29, 2012”, 7 pgs.
“International Application Serial No. PCT/US2012/024366, International Preliminary Report on Patentability dated Aug. 22, 2013”, 20 pgs.
“International Application Serial No. PCT/US2012/024366, International Search Report dated Sep. 7, 2012”, 3 pgs.
“International Application Serial No. PCT/US2012/024366, Invitation to Pay Additional Fees and Partial Search Report dated Jun. 1, 2012”, 3 pgs.
“International Application Serial No. PCT/US2012/024366, Written Opinion dated Sep. 7, 2012”, 18 pgs.
“Japanese Application Serial No. 2011-529290, Office Action dated Sep. 25, 2013”, 5 pgs.
“Japanese Application Serial No. 2013-501497, Office Action dated Nov. 5, 2014”, 7 pgs.
“Stent”, Unabridged (v1.01 ), [Online]. Retrieved from the Internet: <URL: http://dictionary.reference.com/search?q=stent>, (Sep. 22, 2006), 1 pg.
Aaron, Kaplan V, “U.S. Appl. No. 09/225,364, filed Jan. 4, 1999”, (Jan. 4, 1999).
Bernard, Andreas, “U.S. Appl. No. 60/336,607, filed Dec. 3, 2001”.
Bernard, Andreas, “U.S. Appl. No. 60/336,767, filed Dec. 3, 2001”.
Bernard, Andreas, “U.S. Appl. No. 60/440,839, filed Jan. 17, 2003”.
Bernard, Andreas, “U.S. Appl. No. 60/784,309, filed Mar. 20, 2006”.
Bourang, Henry, et al., “U.S. Appl. No. 14/294,631 filed Jun. 3, 2014”, 151 pgs.
Bourang, Henry, et al., “U.S. Appl. No. 14/313,742 filed Jun. 24, 2014”, 142 pgs.
Bourang, Henry, et al., “U.S. Appl. No. 14/314,361 filed Jun. 25, 2014”, 132 pgs.
Bourang, Henry, et al., “U.S. Appl. No. 14/317,387, filed Jun. 27, 2014”, 39 pgs.
Bourang, Henry, et al., “U.S. Appl. No. 14/321,506. filed Jul. 1, 2014”, 131 pgs.
Bourang, Henry, et al., “U.S. Appl. No. 14/621,231, filed Feb. 12, 2015”, 138 pgs.
Bourang, Henry, et al., “U.S. Appl. No. 15/831,110, filed Dec. 1, 2017”, 130 pgs.
Colombo, “The Invatec Bifurcation Stent Solution”, Colombo Bifurcation Stents: Novel Solutions, TCT Washington, (Sep. 15-19, 2003), 24 pgs.
Cooley, Patrick, et al., “Applications of Ink-Jet Printing Technology to BioMEMs and Microfluidic Systems”, Proceedings, SPIE Conference on Microfluidics and BioMEMs, (Oct. 2001), 12 pgs.
Dichek, et al., “Seeding of intravascular stents with genetically engineered endothelial cells”, Circulation. vol. 80, No. 5, (1989), 7 pgs.
Enrique, Klein J, “U.S. Appl. No. 09/097,855, filed Jun. 15, 1998”.
Jeffry, Grainger, “U.S. Appl. No. 60/561,041, filed Apr. 9, 2004”.
Joung, Yoon Ki, et al., “Estrogen Release from Metallic Stent Surface for the Prevention of Restenosis”, Journal of Controlled Release vol. 92, (2003), 83-91.
Lefevre, Thierry, et al., “Approach to Coronary Bifurcation Stenting in 2003”, Euro PCR, (May 2003), 127-154.
Pablo, Acosta, et al., “U.S. Appl. No. 10/874,859, filed Jun. 22, 2004”.
Patrick, Ruane, “U.S. Appl. No. 60/890,703, filed Feb. 20, 2007”.
Patrick, Ruane, “U.S. Appl. No. 61/012,317, filed Dec. 7, 2007”.
Stephen, Kaplan, “U.S. Appl. No. 60/810,522, filed Jun. 2, 2006”.
Stimpson, Donald I, et al., “Parallel Production of Oligonucleotide Arrays Using Membranes and Reagent Jet Printing”, Bio Techniques; vol. 25, (Nov. 1998), 886-890.
Sunmi, Chew, “U.S. Appl. No. 60/336,967, filed Dec. 3, 2001”.
Isunmi, Chew, “U.S. Appl. No. 60/364,389, filed Mar. 13, 2002”.
“U.S. Appl. No. 16/251,767, Final Office Action dated Mar. 23, 2021”, 14 pgs.
“U.S. Appl. No. 16/251,767, Response filed Jun. 23, 2021 to Final Office Action dated Mar. 23, 2021”, 6 pgs.
“U.S. Appl. No. 16/800,905, Non Final Office Action dated May 21, 2021”, 13 pgs.
“U.S. Appl. No. 16/800,905, Response filed Aug. 20, 2021 to Non Final Office Action dated May 21, 2021”, 7 pgs.
“Australian Application Serial No. 2011232357, Response filed Sep. 9, 2015 to First Examination Report dated Dec. 3, 2014”, 2 pgs.
“Australian Application Serial No. 2011232361, Response filed May 5, 2015 to First Examination Report dated Dec. 12, 2014”, 8 pgs.
“Australian Application Serial No. 2011232362, Response filed Nov. 12, 2015 to First Examination Report dated Jan. 11, 2015”, 20 pgs.
“Chinese Application Serial No. 201811453698.7, Office Action dated Mar. 27, 2020”, w/ English Translation, 21 pgs.
“Chinese Application Serial No. 201811453698.7, Response filed Aug. 3, 2020 to Office Action dated Mar. 27, 2020”, w/ English Claims, 16 pgs.
“European Application Serial No. 09816963.4, Communication Pursuant to Article 94(3) EPC dated May 31, 2021”, 5 pgs.
“European Application Serial No. 11760253.2, Communication Pursuant to Article 94(3) EPC dated Mar. 8, 2018”, 5 pgs.
“European Application Serial No. 11760253.2, Response filed Jul. 5, 2018 to Communication Pursuant to Article 94(3) EPC dated Mar. 8, 2018”, 19 pgs.
“European Application Serial No. 11760253.2, Response filed Sep. 20, 2017 to Extended European Search Report dated Feb. 22, 2017”, 30 pgs.
“European Application Serial No. 11760257.3, Intention to Grant dated Jan. 19, 2017”, 5 pgs.
“European Application Serial No. 11760257.3, Response filed Apr. 25, 2013 to Communication pursuant to Rules 161(1) and 162 EPC dated Oct. 31, 2012”, 14 pgs.
“European Application Serial No. 11760257.3, Response filed Apr. 26, 2016 to Extended European Search Report dated Sep. 29, 2015”, 20 pgs.
“European Application Serial No. 19203021.1, Extended European Search Report dated Jan. 28, 2020”, 8 pgs.
“European Application Serial No. 19203021.1, Response filed Sep. 3, 2020 to Extended European Search Report dated Jan. 28, 2020”, 12 pgs.
“International Application Serial No. PCT/US2011/029858, International Preliminary Report on Patentability dated Oct. 4, 2012”, 9 pgs.
“U.S. Appl. No. 17/143,015, filed Jul. 17, 2023 to Restriction Requirement dated Apr. 17, 2023”, 6 pgs.
“European Application Serial No. 22191182.9, Extended European Search Report dated Nov. 22, 2022”, 4 pgs.
“U.S. Appl. No. 17/143,015, Restriction Requirement dated Apr. 17, 2023”, 7 pgs.
Related Publications (1)
Number Date Country
20210220156 A1 Jul 2021 US
Provisional Applications (1)
Number Date Country
61194346 Sep 2008 US
Divisions (1)
Number Date Country
Parent 13071149 Mar 2011 US
Child 14317387 US
Continuations (3)
Number Date Country
Parent 15661975 Jul 2017 US
Child 17222573 US
Parent 14317387 Jun 2014 US
Child 15661975 US
Parent PCT/US2009/058505 Sep 2009 US
Child 13071149 US